clonidine has been researched along with Addiction, Opioid in 241 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study goal was to determine whether clonidine treatment of neonatal abstinence syndrome (NAS) would result in a better neurobehavioral performance compared with morphine." | 9.20 | Morphine versus clonidine for neonatal abstinence syndrome. ( Bada, HS; Breheny, P; Caldwell, R; Capilouto, G; Garlitz, K; Gibson, J; Leggas, M; Li, Y; Sithisarn, T, 2015) |
| "The use of clonidine in the management of opiate abstinence is presented in a patient dependent upon levorphanol tartrate given for chronic pain." | 7.66 | The use of clonidine for management of opiate abstinence in a chronic pain patient. ( Bakris, GL; Cross, PD; Hammarsten, JE, 1982) |
| "Clonidine therapy was used to alleviate symptoms of narcotic analgesic withdrawal." | 5.27 | Narcotic bowel syndrome treated with clonidine. Resolution of abdominal pain and intestinal pseudo-obstruction. ( Greenberger, NJ; McPhee, MS; Sandgren, JE, 1984) |
| "The study goal was to determine whether clonidine treatment of neonatal abstinence syndrome (NAS) would result in a better neurobehavioral performance compared with morphine." | 5.20 | Morphine versus clonidine for neonatal abstinence syndrome. ( Bada, HS; Breheny, P; Caldwell, R; Capilouto, G; Garlitz, K; Gibson, J; Leggas, M; Li, Y; Sithisarn, T, 2015) |
| "Opioid detoxification is not an effective stand-alone treatment for heroin dependence but is nevertheless an essential step in the path to recovery." | 5.15 | Outpatient versus inpatient opioid detoxification: a randomized controlled trial. ( Day, E; Strang, J, 2011) |
| "Overall, the combination of Buprenorphine and Valproate seems to be a safe and promising method for treating multiple drug withdrawal symptoms." | 5.12 | Treatment of polydrug-using opiate dependents during withdrawal: towards a standardisation of treatment. ( Clausen, T; Isaksen, A; Kristensen, Ø; Lølandsmo, T; Vederhus, JK, 2006) |
| "Mu-opioid receptor blockade by naloxone administered for acute detoxification in patients addicted to opioids markedly increases catecholamine plasma concentrations, muscle sympathetic activity (MSA), and is associated with cardiovascular stimulation despite general anesthesia." | 5.10 | Sympathetic neural activation evoked by mu-receptor blockade in patients addicted to opioids is abolished by intravenous clonidine. ( Gastpar, M; Heuter, T; Kienbaum, P; Michel, MC; Peters, J; Scherbaum, N, 2002) |
| " During general anesthesia lasting about six hours with methohexital or propofol, naloxone was administered with doubling of the dose every 15 minutes with a starting bolus dose of 0." | 5.08 | Alternative strategies of opiate detoxification: evaluation of the so-called ultra-rapid detoxification. ( Gastpar, M; Kaube, H; Kienbaum, P; Klein, S; Peters, J; Scherbaum, N, 1998) |
| " We present a case report of a neonate born to a 25-year-old mother enrolled in a medication-assisted treatment program for substance use disorder who was noncompliant in prenatal care, using multiple substances throughout the pregnancy, including gabapentin and fentanyl." | 3.91 | Novel Withdrawal Symptoms of a Neonate Prenatally Exposed to a Fentanyl Analog. ( Davies, TH; Hansen, Z; Loudin, S; Murray, S; Nellhaus, EM, 2019) |
| "The use of clonidine in the management of opiate abstinence is presented in a patient dependent upon levorphanol tartrate given for chronic pain." | 3.66 | The use of clonidine for management of opiate abstinence in a chronic pain patient. ( Bakris, GL; Cross, PD; Hammarsten, JE, 1982) |
| "Pharmacotherapeutic options for the treatment of opioid withdrawal are limited by abuse potential, adverse effects, and lack of availability of existing drugs." | 3.01 | Efficacy and safety of tramadol in the treatment of opioid withdrawal: A meta-analysis of randomized controlled trials. ( Maiti, R; Mishra, BR; Mohapatra, D; Padhan, M, 2023) |
| "Lofexidine (LFX), an α2A adrenergic receptor agonist, known to alleviate opioid withdrawal symptoms, was assessed in combination with oral naltrexone (NTX) for effects on opioid use outcomes and NTX treatment compliance." | 2.90 | Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study. ( Fogelman, N; Hermes, G; Hyman, SM; Kosten, TR; Sinha, R, 2019) |
| "Lofexidine was at least as effective as diazepam in reducing the opioid withdrawal syndrome and increased treatment retention." | 2.87 | Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: A double-blind randomized clinical trial in Singapore. ( Assam, PN; Chan, E; Cheok, C; de Souza, NN; Guo, S; Kandasami, G; Koh, PK; Lee, KM; Manning, V; Pangjaya, J; Sultana, R; Wijesinghe, R; Wong, KE; Yang, Y, 2018) |
| "During induction/stabilisation, withdrawal symptoms subsided more slowly for buprenorphine/naloxone than for methadone, and craving was significantly higher in the buprenorphine/naloxone group ( p<0." | 2.84 | Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals. ( Coulton, S; Diaper, AM; Law, FD; Melichar, JK; Myles, JS; Nutt, DJ, 2017) |
| "These results demonstrate the safety, efficacy, and tolerability of low-dose naltrexone, in conjunction with single-day buprenorphine dosing and adjunctive nonopioid medications, for initiating adults with opioid dependence to XR-naltrexone." | 2.84 | Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine. ( Bisaga, A; Carpenter, KM; Choi, CJ; Dakwar, E; Levin, FR; Mariani, JJ; Mishlen, K; Nunes, EV; Pavlicova, M; Sullivan, M, 2017) |
| "Lofexidine is an alpha-2-adrenergic receptor agonist approved in the United Kingdom (UK) for the treatment of opioid withdrawal symptoms." | 2.84 | A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. ( Biswas, K; Gorodetzky, CW; Gullo, KL; Martin, PR; Saxon, AJ; Walsh, SL, 2017) |
| "The intensity of withdrawal in opiate dependence shows a high inter-individual variability." | 2.74 | Intensity of opiate withdrawal in relation to the 825C>T polymorphism of the G-protein beta 3 subunit gene. ( Augener, S; Bachmann, HS; Bonnet, U; Lieb, B; Scherbaum, N; Siffert, W; Specka, M, 2009) |
| "Lofexidine is an orally bioavailable alpha 2-adrenergic receptor agonist analogue of clonidine that acts centrally to suppress opiate withdrawal symptoms." | 2.73 | Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. ( Akerele, E; Al-Ghananeem, AM; Elkashef, A; Fischman, MW; Herman, BH; Kleber, H; Ling, W; Miotto, K; O'Brien, CP; Yu, E, 2008) |
| "All patients met the DSM IV criteria for opioid dependence." | 2.70 | Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial. ( Ahmadi-Abhari, SA; Akhondzadeh, S; Assadi, SM; Farzanehgan, ZM; Kamlipour, A; Shabestari, OL, 2001) |
| "Trazodone is a non-tricyclic antidepressant drug with specific antagonistic activities at 5-HT(2) and alpha-1 adrenoceptors." | 2.69 | Combined use of trazodone-naltrexone versus clonidine-naltrexone in rapid withdrawal from methadone treatment. A comparative inpatient study. ( Conte, G; De Risio, S; Pozzi, G, 2000) |
| "Withdrawal symptoms were significantly less severe on days 4-7, and 9-13, in the naltrexone/lofexidine combination group." | 2.69 | Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification. ( Bearn, J; Buntwal, N; Gossop, M; Strang, J, 2000) |
| "Significant differences in levels of withdrawal symptoms were found on days 11, 13-15 and 17-20, symptoms resolving most rapidly in the 5-day lofexidine treatment group, whilst withdrawal responses in the 10-day lofexidine treatment group were intermediate between the 5-day lofexidine and standard methadone treatment conditions." | 2.69 | Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. ( Bearn, J; Gossop, M; Strang, J, 1998) |
| "Buprenorphine (BUP) is an alternative to methadone (METH) maintenance." | 2.68 | A protocol to switch high-dose, methadone-maintained subjects to buprenorphine. ( Connerney, I; Fischman, MW; Foltin, RW; Levin, FR, 1997) |
| "Twenty eight opiate addicted inpatients who had been stabilised on methadone took part in a double-blind randomised trial of clonidine and lofexidine (14 on each treatment) for opiate detoxification: clonidine or lofexidine dosage was titrated according to symptoms." | 2.68 | Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. ( Beckford, H; Kahn, A; Mumford, JP; Rogers, GA, 1997) |
| "Clonidine was more effective than lefetamine in suppressing withdrawal in the first 3 days of treatment (day 3: F = 4." | 2.67 | Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. ( Janiri, L; Mannelli, P; Persico, AM; Serretti, A; Tempesta, E, 1994) |
| "Clonidine appears to be a safe and efficacious outpatient treatment for opiate withdrawal, although the results were less favorable than those obtained in open or inpatient studies." | 2.66 | Clonidine in outpatient detoxification from methadone maintenance. ( Charney, D; Gaspari, J; Hogan, I; Kleber, HD; Kosten, T; O'Connor, C; Riordan, CE; Rounsaville, B, 1985) |
| "Lofexidine has been shown to be effective in reducing the former and could potentially aid in recovery and withdrawal." | 2.66 | A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms. ( Berger, AA; Hasoon, J; Jung, JW; Kassem, H; Kaye, AD; Mousa, M; Patel, A; Urits, I; Virgen, CG; Viswanath, O; Zusman, R, 2020) |
| "Clonidine was effective but had a differential effect on the signs and symptoms of morphine abstinence." | 2.66 | Clonidine in morphine withdrawal. Differential effects on signs and symptoms. ( Jasinski, DR; Johnson, RE; Kocher, TR, 1985) |
| "Clonidine, 0." | 2.66 | Effect of clonidine on plasma beta-endorphin, cortisol and growth hormone secretion in opiate-addicted subjects. ( Bar-Yoseph, J; Gil-Ad, I; Laron, Z; Smadja, Y; Zohar, M, 1985) |
| " Under controlled inpatient conditions established to assess dosage guidelines and to examine specific signs and symptoms of withdrawal, ten (91%) of 11 patients were able to withdraw completely from methadone therapy by the end of a six-day period." | 2.65 | Clonidine and naltrexone. A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy. ( Braverman, P; Charney, DS; Heninger, GR; Kleber, HD; Murburg, M; Redmond, DE; Riordan, CE; Sternberg, DE, 1982) |
| "Lofexidine might prove to be a safer and more effective nonopiate treatment for opiate withdrawal, especially for ambulatory outpatients; controlled studies are required to confirm this possibility." | 2.65 | Opiate withdrawal using lofexidine, a clonidine analogue with fewer side effects. ( Geyer, G; Resnick, RB; Washton, AM, 1983) |
| "Lofexidine is an effective and safe agent in treating symptoms related to opioid withdrawal in adults when compared with placebo; although it is more widely accessible than other first-line therapies, its use in practice may be limited by cost." | 2.61 | Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal. ( Brooks, T; Doughty, B; Morgenson, D, 2019) |
| "When opioid misuse rises in the United States, pregnant women and their neonates are affected." | 2.61 | Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome. ( Jones, HE; Kraft, WK, 2019) |
| "Buprenorphine was superior to clonidine in controlling severe withdrawal symptoms in an outpatient setting (RR 0." | 2.58 | Pharmacological therapies for management of opium withdrawal. ( Amato, L; Amin-Esmaeili, M; Gholami, J; Hoseinie, L; Rahimi-Movaghar, A; Yousefi-Nooraie, R, 2018) |
| "Opioid dependence is a significant public health problem associated with high risk for relapse if treatment is not ongoing." | 2.48 | Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. ( Bisaga, A; Kosten, T; Nunes, EV; O'Connor, PG; Sigmon, SC; Woody, G, 2012) |
| "Lofexidine is an alpha(2)-agonist structurally related to clonidine." | 2.46 | Lofexidine, an {alpha}2-receptor agonist for opioid detoxification. ( Gish, EC; Honey, BL; Johnson, PN; Miller, JL, 2010) |
| "Pharmacotherapy of opioid addiction alone is usually insufficient, and a complete treatment should also include effective psychosocial support or other interventions." | 2.46 | The pharmacological treatment of opioid addiction--a clinical perspective. ( Bramness, J; Gossop, M; Lobmaier, P; Waal, H, 2010) |
| "Buprenorphine and methadone were ranked as the most effective methods of opioid detoxification followed by lofexidine and clonidine respectively." | 2.46 | A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis. ( Meader, N, 2010) |
| "Methadone maintenance treatment (MMT) has not been officially approved by the Chinese government for widespread implementation, but some pilot studies are currently underway." | 2.43 | Opiate addiction in China: current situation and treatments. ( Cubells, JF; Tang, YL; Zhao, C; Zhao, D, 2006) |
| "Lofexidine is an alpha-2 adrenergic agonist that is increasingly used in the management of opiate withdrawal--notably in the UK." | 2.40 | Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. ( Bearn, J; Gossop, M; Strang, J, 1999) |
| " Blood specimens were generally not collected from 0-15 minutes after intravenous dosing 6." | 2.38 | Clinical toxicology of drugs used in the treatment of opiate dependency. ( Fraser, AD, 1990) |
| "Clonidine has provided a nonaddicting solution to an ancient problem, opiate withdrawal without opiates." | 2.37 | Clonidine. ( Gold, MS; Roehrich, H, 1987) |
| " Narcotics are used for the euphoria they provide; however, chronic use results in physiological and psychological changes." | 2.37 | Narcotic withdrawal in the emergency department. ( Freitas, PM, 1985) |
| "The chapters on opioid dependence in the 26 editions of Cecil Textbook of Medicine published from 1927 through 2020." | 1.72 | Pharmacological Management of Heroin Withdrawal Syndrome: A Century of Expert Opinions in Cecil Textbook of Medicine. ( Manu, P; Rogozea, LM; Shulman, M, 2022) |
| "Methadone and buprenorphine have pharmacologic properties that are concerning for a high risk of drug-drug interactions (DDIs)." | 1.72 | Identifying Clinically Relevant Drug-Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal Detection. ( Acton, EK; Bilker, WB; Brensinger, CM; Dawwas, GK; Hennessy, S; Leonard, CE; Li, L; Miano, TA; Neuman, M; Nguyen, TPP; Soprano, SE; Wang, L; Woody, G; Yu, E, 2022) |
| "Opioid use disorder is a growing concern in the United States." | 1.62 | Validation and characterization of oxycodone physical dependence in C57BL/6J mice. ( Beardsley, PM; Carper, M; Contreras, KM; Damaj, MI; Walentiny, DM, 2021) |
| "Clonidine treatment significantly increased fentanyl-vs." | 1.51 | Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats. ( Banks, ML; Blake, S; Bremer, PT; Faunce, KE; Hwang, CS; Janda, KD; Natori, Y; Townsend, EA; Zhou, B, 2019) |
| "Lofexidine would likely have been excluded for further development in this day and age given the existence and value of clonidine as well as the lack of insurance coverage for opiate addiction." | 1.40 | The preclinical discovery of lofexidine for the treatment of opiate addiction. ( Vartak, AP, 2014) |
| " At each daily visit, signs and symptoms were assessed, and medications and dosing instructions were given for the following 24 hours." | 1.37 | A nonopioid procedure for outpatient opioid detoxification. ( Baier, AR; Coons, EE; Fingesten, A; Ockert, DM; Volpicelli, JR, 2011) |
| "The average half-life obtained from all profiles was 12." | 1.35 | Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients. ( Abbassi, M; Al Ghananeem, AM; Herman, BH; Ling, W; Miotto, K; Montgomery, A; O'Brien, CP; Walsh, R; Yu, E, 2009) |
| "Methadone was tapered and discontinued prior to ROD and Naltrexone was administered in increasing daily doses." | 1.32 | Unexpected delirium during Rapid Opioid Detoxification (ROD). ( Golden, SA; Sakhrani, DL, 2004) |
| "Its efficacy and tolerance in treating withdrawal symptoms is, however, suboptimal." | 1.31 | Topiramate in opiate withdrawal. ( Besson, J; Cottier, AC; Zullino, DF, 2002) |
| "Buprenorphine is a partial opiate agonist with unusual pharmacological properties." | 1.31 | Two methods of community detoxification from opiates: an open-label comparison of lofexidine and buprenorphine. ( Alcorn, R; Feinmann, C; White, R, 2001) |
| "Women with mild withdrawal symptoms were given clonidine initially, and methadone was substituted if symptoms persisted." | 1.30 | Opioid detoxification in pregnancy. ( Dashe, JS; Jackson, GL; Olscher, DA; Wendel, GD; Zane, EH, 1998) |
| "These findings indicate that opioid dependence induces efficacious coupling of mu-receptors to presynaptic inhibition in GABAergic nerve terminals via adenylyl cyclase- and protein kinase A-dependent processes in PAG." | 1.30 | Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway. ( Bagley, EE; Christie, MJ; Connor, M; Ingram, SL; Vaughan, CW, 1998) |
| "Clonidine use was assessed in 90 treatment-seeking, pregnant, opiate-abusing women using both self-report and urinalysis toxicology." | 1.30 | Illicit use of clonidine in opiate-abusing pregnant women. ( Anderson, F; Huggins, G; Lee, J; Paluzzi, P; Svikis, D, 1997) |
| "Tizanidine was administered orally at 0." | 1.30 | Effects of tizanidine administration on precipitated opioid withdrawal signs in rats. ( Pinelli, A; Spezia, R; Trivulzio, S, 1998) |
| "Relapse was defined as at least two weeks of daily opiate use." | 1.30 | Outcomes of ultrarapid opiate detoxification combined with naltrexone maintenance and counseling. ( Cohen, H; Kotler, M; Rabinowitz, J, 1998) |
| "Clonidine therapy was used to alleviate symptoms of narcotic analgesic withdrawal." | 1.27 | Narcotic bowel syndrome treated with clonidine. Resolution of abdominal pain and intestinal pseudo-obstruction. ( Greenberger, NJ; McPhee, MS; Sandgren, JE, 1984) |
| "Clonidine has been used successfully in the treatment of opiate dependence." | 1.27 | Influence of clonidine on the acute dependence response elicited in naive rats by naloxone. ( Eisenberg, RM, 1983) |
| "Clonidine (Catapres) is a safe and effective agent for detoxification of selected opiate addicts." | 1.27 | Opiate and cocaine dependencies. Techniques to help counter the rising tide. ( Gold, MS; Pottash, AC; Washton, AM, 1985) |
| "Clonidine-treated patients had significantly fewer symptoms than a comparable group of opioid addicts abruptly withdrawn from methadone." | 1.26 | Clonidine suppresses the opioid abstinence syndrome without clonidine-withdrawal symptoms: a blind inpatient study. ( Kleber, HD; Redmond, DE; Uhde, TW, 1980) |
| "Clonidine is an effective emergency treatment for acute opiate withdrawal and in the detoxification of methadone, heroin, and other opiate addictions." | 1.26 | Clonidine: inpatient studies from 1978 to 1981. ( Extein, I; Gold, MS; Pottash, AL, 1982) |
| "Clonidine was administered to nineteen patients in an inpatient setting after abrupt discontinuation of chronic opiate addiction (morphine, héroin, dextromoramide)." | 1.26 | [Effects of clonidine on opiate withdrawal symptoms. Results - biochemical mechanisms (author's transl)]. ( Escande, M; Gardes, JP; Girard, M; Granier, F, 1982) |
| "Clonidine hydrochloride was administered to ten patients in an inpatient setting after abrupt discontinuation of chronic methadone hydrochloride administration." | 1.26 | Opiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment. ( Gold, MS; Kleber, HD; Pottash, AC; Sweeney, DR, 1980) |
| "The development of opioid dependence and tolerance attributed to selective types of opiate receptors was studied in the isolated ileum of guinea pigs chronically exposed to specific opioids." | 1.26 | Opioid dependence and cross-dependence in the isolated guinea-pig ileum. ( Herz, A; Schulz, R; Seidl, E; Wüster, M, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 82 (34.02) | 18.7374 |
| 1990's | 39 (16.18) | 18.2507 |
| 2000's | 54 (22.41) | 29.6817 |
| 2010's | 52 (21.58) | 24.3611 |
| 2020's | 14 (5.81) | 2.80 |
| Authors | Studies |
|---|---|
| Manu, P | 1 |
| Rogozea, LM | 1 |
| Shulman, M | 1 |
| Miano, TA | 1 |
| Wang, L | 1 |
| Leonard, CE | 1 |
| Brensinger, CM | 1 |
| Acton, EK | 1 |
| Dawwas, GK | 1 |
| Bilker, WB | 1 |
| Soprano, SE | 1 |
| Nguyen, TPP | 1 |
| Woody, G | 4 |
| Yu, E | 3 |
| Neuman, M | 1 |
| Li, L | 1 |
| Hennessy, S | 1 |
| Dersch-Mills, D | 1 |
| Howlett, A | 1 |
| Lind, J | 1 |
| Marchuk, A | 1 |
| Mohammad, K | 1 |
| Bhenderu, LS | 1 |
| Lyon, KA | 1 |
| Soto, JM | 1 |
| Richardson, W | 1 |
| Desai, R | 1 |
| Rahm, M | 1 |
| Huang, JH | 1 |
| Padhan, M | 1 |
| Maiti, R | 1 |
| Mohapatra, D | 1 |
| Mishra, BR | 1 |
| Gedda, C | 1 |
| Nygren, J | 1 |
| Garpenbeck, A | 1 |
| Hoffström, L | 1 |
| Thorell, A | 1 |
| Soop, M | 1 |
| Ratnasekara, V | 1 |
| Weinberg, L | 1 |
| Johnston, SA | 1 |
| Fletcher, L | 1 |
| Nugraha, P | 1 |
| Cox, DRA | 1 |
| Hu, R | 1 |
| Meyer, I | 1 |
| Yoshino, O | 1 |
| Perini, MV | 1 |
| Muralidharan, V | 1 |
| Nikfarjam, M | 1 |
| Lee, DK | 1 |
| Hermes, G | 1 |
| Hyman, SM | 1 |
| Fogelman, N | 1 |
| Kosten, TR | 5 |
| Sinha, R | 2 |
| Urits, I | 1 |
| Patel, A | 1 |
| Zusman, R | 1 |
| Virgen, CG | 1 |
| Mousa, M | 1 |
| Berger, AA | 1 |
| Kassem, H | 1 |
| Jung, JW | 1 |
| Hasoon, J | 1 |
| Kaye, AD | 1 |
| Viswanath, O | 1 |
| Dunn, K | 1 |
| Bergeria, C | 1 |
| Huhn, AS | 2 |
| Strain, EC | 3 |
| Hilas, O | 1 |
| Caliendo, T | 1 |
| Carper, M | 1 |
| Contreras, KM | 1 |
| Walentiny, DM | 1 |
| Beardsley, PM | 1 |
| Damaj, MI | 1 |
| Zankl, A | 2 |
| Martin, J | 2 |
| Davey, JG | 2 |
| Osborn, DA | 5 |
| Gorodetzky, CW | 2 |
| Walsh, SL | 1 |
| Martin, PR | 1 |
| Saxon, AJ | 1 |
| Gullo, KL | 1 |
| Biswas, K | 1 |
| Gowing, L | 8 |
| Ali, R | 8 |
| White, JM | 6 |
| Law, FD | 1 |
| Diaper, AM | 1 |
| Melichar, JK | 1 |
| Coulton, S | 1 |
| Nutt, DJ | 1 |
| Myles, JS | 1 |
| Dunn, KE | 2 |
| Tompkins, DA | 2 |
| Bigelow, GE | 4 |
| Rudolf, G | 1 |
| Walsh, J | 1 |
| Plawman, A | 1 |
| Gianutsos, P | 1 |
| Alto, W | 1 |
| Mancl, L | 1 |
| Rudolf, V | 1 |
| Hoyt, MR | 1 |
| Shah, U | 1 |
| Cooley, J | 1 |
| Temple, M | 1 |
| Kowalczyk, WJ | 2 |
| Moran, LM | 1 |
| Bertz, JW | 1 |
| Phillips, KA | 2 |
| Ghitza, UE | 2 |
| Vahabzadeh, M | 1 |
| Lin, JL | 1 |
| Epstein, DH | 3 |
| Preston, KL | 5 |
| Guo, S | 1 |
| Manning, V | 1 |
| Yang, Y | 1 |
| Koh, PK | 1 |
| Chan, E | 1 |
| de Souza, NN | 1 |
| Assam, PN | 1 |
| Sultana, R | 1 |
| Wijesinghe, R | 1 |
| Pangjaya, J | 1 |
| Kandasami, G | 1 |
| Cheok, C | 1 |
| Lee, KM | 1 |
| Wong, KE | 1 |
| Rahimi-Movaghar, A | 1 |
| Gholami, J | 1 |
| Amato, L | 3 |
| Hoseinie, L | 1 |
| Yousefi-Nooraie, R | 1 |
| Amin-Esmaeili, M | 1 |
| Traynor, K | 1 |
| Weerts, EM | 1 |
| Schroeder, JR | 2 |
| Nellhaus, EM | 1 |
| Murray, S | 1 |
| Hansen, Z | 1 |
| Loudin, S | 1 |
| Davies, TH | 1 |
| Klein, LR | 1 |
| Cole, JB | 1 |
| Driver, BE | 1 |
| Miner, JR | 1 |
| Laes, JR | 1 |
| Fagerstrom, E | 1 |
| L Martel, M | 1 |
| Doughty, B | 1 |
| Morgenson, D | 1 |
| Brooks, T | 1 |
| Bryce, C | 1 |
| Ward, HB | 1 |
| Barnett, BS | 1 |
| Suzuki, J | 1 |
| Jones, HE | 1 |
| Kraft, WK | 1 |
| Townsend, EA | 1 |
| Blake, S | 1 |
| Faunce, KE | 1 |
| Hwang, CS | 1 |
| Natori, Y | 1 |
| Zhou, B | 1 |
| Bremer, PT | 1 |
| Janda, KD | 1 |
| Banks, ML | 1 |
| Srivastava, A | 1 |
| Kahan, M | 1 |
| Njoroge, I | 1 |
| Sommer, LZ | 1 |
| Parikh, A | 1 |
| Gopalakrishnan, M | 1 |
| Azeem, A | 1 |
| Booth, A | 1 |
| El-Metwally, D | 1 |
| Minozzi, S | 2 |
| Bellisario, C | 1 |
| Davoli, M | 2 |
| Albertson, TE | 1 |
| Chenoweth, J | 1 |
| Ford, J | 1 |
| Owen, K | 1 |
| Sutter, ME | 1 |
| Vartak, AP | 1 |
| Fresquez-Chavez, KR | 1 |
| Fogger, S | 1 |
| Bada, HS | 1 |
| Sithisarn, T | 1 |
| Gibson, J | 1 |
| Garlitz, K | 1 |
| Caldwell, R | 1 |
| Capilouto, G | 1 |
| Li, Y | 1 |
| Leggas, M | 1 |
| Breheny, P | 1 |
| Jobes, ML | 1 |
| Kennedy, AP | 1 |
| Agage, DA | 1 |
| Schmittner, JP | 1 |
| Mogali, S | 1 |
| Khan, NA | 1 |
| Drill, ES | 1 |
| Pavlicova, M | 2 |
| Sullivan, MA | 1 |
| Nunes, E | 1 |
| Bisaga, A | 3 |
| deWit, H | 1 |
| Schwarzkopf, R | 1 |
| Drexler, M | 1 |
| Ma, MW | 1 |
| Schultz, VM | 1 |
| Le, KT | 1 |
| Rutenberg, TF | 1 |
| Rinehart, JB | 1 |
| Vernon, MK | 1 |
| Reinders, S | 1 |
| Mannix, S | 1 |
| Gullo, K | 1 |
| Clinch, T | 1 |
| Farrell, M | 3 |
| Naguy, A | 1 |
| Ayanga, D | 1 |
| Shorter, D | 1 |
| Weinstein, ZM | 1 |
| Cheng, DM | 1 |
| Quinn, E | 1 |
| Hui, D | 1 |
| Kim, H | 1 |
| Gryczynski, G | 1 |
| Samet, JH | 1 |
| Sullivan, M | 1 |
| Choi, CJ | 1 |
| Mishlen, K | 1 |
| Carpenter, KM | 1 |
| Levin, FR | 2 |
| Dakwar, E | 1 |
| Mariani, JJ | 1 |
| Nunes, EV | 2 |
| Mbewe, D | 1 |
| Ziedonis, DM | 1 |
| Amass, L | 3 |
| Steinberg, M | 1 |
| Krejci, J | 2 |
| Annon, JJ | 2 |
| Cohen, AJ | 1 |
| Waite-O'Brien, N | 1 |
| Stine, SM | 1 |
| McCarty, D | 2 |
| Reid, MS | 1 |
| Brown, LS | 1 |
| Maslansky, R | 1 |
| Winhusen, T | 2 |
| Babcock, D | 2 |
| Brigham, G | 2 |
| Muir, J | 2 |
| Orr, D | 2 |
| Buchan, BJ | 1 |
| Horton, T | 1 |
| Ling, W | 4 |
| Miotto, K | 2 |
| Akerele, E | 1 |
| O'Brien, CP | 3 |
| Kleber, H | 3 |
| Fischman, MW | 2 |
| Elkashef, A | 1 |
| Herman, BH | 2 |
| Al-Ghananeem, AM | 1 |
| Lieb, B | 1 |
| Bonnet, U | 1 |
| Specka, M | 1 |
| Augener, S | 1 |
| Bachmann, HS | 1 |
| Siffert, W | 1 |
| Scherbaum, N | 3 |
| Schmittner, J | 1 |
| Krantz, MJ | 1 |
| Eid, NC | 1 |
| Al Ghananeem, AM | 1 |
| Abbassi, M | 1 |
| Montgomery, A | 1 |
| Walsh, R | 1 |
| Honey, BL | 2 |
| Benefield, RJ | 1 |
| Miller, JL | 2 |
| Johnson, PN | 2 |
| Gish, EC | 1 |
| Meader, N | 1 |
| Lobmaier, P | 1 |
| Gossop, M | 7 |
| Waal, H | 1 |
| Bramness, J | 1 |
| Jeffery, HE | 3 |
| Cole, MJ | 3 |
| Day, E | 1 |
| Strang, J | 6 |
| Williams, BS | 1 |
| Wong, D | 1 |
| Amin, S | 1 |
| Ockert, DM | 1 |
| Volpicelli, JR | 1 |
| Baier, AR | 1 |
| Coons, EE | 1 |
| Fingesten, A | 1 |
| Tonner, PH | 1 |
| Paris, A | 1 |
| Moore, SK | 1 |
| Marsch, LA | 2 |
| Badger, GJ | 2 |
| Solhkhah, R | 1 |
| Hofstein, Y | 1 |
| Mannelli, P | 3 |
| Peindl, K | 2 |
| Wu, LT | 2 |
| Patkar, AA | 2 |
| Gorelick, DA | 1 |
| Sigmon, SC | 1 |
| O'Connor, PG | 3 |
| Kosten, T | 3 |
| Steele, A | 1 |
| Cunningham, P | 1 |
| Praveen, KT | 1 |
| Law, F | 1 |
| O'Shea, J | 1 |
| Melichar, J | 1 |
| Zullino, DF | 2 |
| Cottier, AC | 1 |
| Besson, J | 1 |
| Oliveto, A | 1 |
| Sevarino, K | 1 |
| McCance-Katz, E | 1 |
| Benios, T | 1 |
| Poling, J | 1 |
| Feingold, A | 1 |
| Ma, H | 1 |
| Tang, J | 1 |
| White, PF | 2 |
| Wender, RH | 2 |
| Leverone, T | 1 |
| Quon, R | 1 |
| Pearce, S | 1 |
| Chiao, F | 1 |
| Erice, S | 1 |
| Reti, IM | 1 |
| Baraban, JM | 1 |
| Schnoll, SH | 2 |
| Golden, SA | 1 |
| Sakhrani, DL | 1 |
| White, J | 3 |
| Fiscella, K | 1 |
| Moore, A | 1 |
| Engerman, J | 1 |
| Meldrum, S | 1 |
| Durst, P | 1 |
| Palazzolo, J | 1 |
| Peyrelong, JP | 1 |
| Berger, M | 1 |
| Chalabreysse, M | 1 |
| Billiard, M | 1 |
| Vialle, A | 1 |
| Shoptaw, S | 1 |
| Hillhouse, M | 1 |
| Harrer, J | 1 |
| Reid, M | 1 |
| Buchan, B | 1 |
| Ziedonis, D | 1 |
| Krenz, S | 1 |
| Zimmerman, G | 1 |
| Miozzari, A | 1 |
| Rajeswaran, R | 1 |
| Kolly, S | 1 |
| Khazaal, Y | 1 |
| Glasper, A | 1 |
| Reed, LJ | 1 |
| de Wet, CJ | 1 |
| Bearn, J | 5 |
| Bickel, WK | 1 |
| Stothart, ME | 1 |
| Quesnel, KJ | 1 |
| Stanger, C | 1 |
| Brooklyn, J | 1 |
| Raistrick, D | 1 |
| West, D | 1 |
| Finnegan, O | 1 |
| Thistlethwaite, G | 1 |
| Brearley, R | 1 |
| Banbery, J | 1 |
| Contreras, JA | 1 |
| de Jong, CJ | 1 |
| Wallen, MC | 1 |
| Lorman, WJ | 1 |
| Gosciniak, JL | 1 |
| Tang, YL | 1 |
| Zhao, D | 1 |
| Zhao, C | 1 |
| Cubells, JF | 1 |
| Mackenzie, JW | 1 |
| McCambridge, J | 1 |
| Beswick, T | 1 |
| Best, D | 1 |
| Rees, S | 1 |
| Kristensen, Ø | 1 |
| Lølandsmo, T | 1 |
| Isaksen, A | 1 |
| Vederhus, JK | 1 |
| Clausen, T | 1 |
| Kimmerling, A | 1 |
| Doebrick, C | 1 |
| Rieckmann, T | 1 |
| Daley, M | 1 |
| Fuller, BE | 1 |
| Thomas, CP | 1 |
| Brigham, GS | 1 |
| Harrer, JM | 1 |
| Pelt, A | 1 |
| Firoozabadi, A | 1 |
| Mowla, A | 1 |
| Farashbandi, H | 1 |
| Gorman, JM | 1 |
| Murray, HW | 1 |
| Hubbard, R | 1 |
| Washton, AM | 14 |
| Pottash, AC | 6 |
| Gold, MS | 21 |
| Ginzburg, HM | 2 |
| Glass, WJ | 1 |
| Rawson, RA | 3 |
| Resnick, RB | 10 |
| Tennant, FS | 1 |
| Riordan, CE | 3 |
| Kleber, HD | 18 |
| Korczyn, AD | 1 |
| Pottash, AL | 9 |
| Extein, I | 6 |
| Trommer, PR | 1 |
| Redmond, DE | 4 |
| Sandgren, JE | 1 |
| McPhee, MS | 1 |
| Greenberger, NJ | 1 |
| Bakris, GL | 2 |
| Extein, IL | 1 |
| Huang, YH | 1 |
| Girard, M | 1 |
| Escande, M | 1 |
| Granier, F | 1 |
| Gardes, JP | 1 |
| Schulz, R | 1 |
| Seidl, E | 1 |
| Wüster, M | 1 |
| Herz, A | 1 |
| Robson, LE | 1 |
| Mucha, RF | 1 |
| Kosterlitz, HW | 1 |
| Cuthbert, NJ | 1 |
| Francis, DL | 1 |
| Collier, HO | 1 |
| Geyer, G | 1 |
| Dackis, CA | 2 |
| Liebson, IA | 2 |
| Gillespie, B | 1 |
| Schloemer, NF | 1 |
| Skidmore, JW | 1 |
| Lian, QS | 1 |
| Schaut, J | 1 |
| Eisenberg, RM | 1 |
| Annitto, W | 1 |
| Bourgeois, M | 1 |
| Tignol, J | 1 |
| Daubech, JF | 1 |
| Daulouede, JP | 1 |
| Allison, W | 1 |
| Allison, F | 1 |
| de Saint-Affrique, H | 1 |
| Meggle, D | 1 |
| Keup, W | 3 |
| Perzel, JF | 1 |
| Garwood, J | 1 |
| Sweeney, DR | 5 |
| Annitto, WJ | 1 |
| Johnson, MM | 1 |
| Uhde, TW | 1 |
| Finn, LB | 2 |
| Barchas, JD | 1 |
| Madden, J | 1 |
| Mefford, IN | 1 |
| Cross, PD | 1 |
| Hammarsten, JE | 1 |
| Charney, DS | 2 |
| Murburg, M | 1 |
| Braverman, P | 1 |
| Sternberg, DE | 1 |
| Heninger, GR | 1 |
| Caffrey, DL | 1 |
| Yoo, TP | 1 |
| Andreasen, NE | 1 |
| Knop, J | 1 |
| Jacobsen, KR | 1 |
| Skinhøj, P | 1 |
| Dragsted, L | 1 |
| Andersson, J | 1 |
| Digregorio, GJ | 1 |
| Bukovinsky, MA | 1 |
| Hoder, EL | 1 |
| Leckman, JF | 1 |
| Ehrenkranz, R | 1 |
| Cohen, DJ | 1 |
| Poulsen, JA | 1 |
| Davies, RK | 1 |
| Masini, E | 1 |
| Blandina, P | 1 |
| Mannaioni, PF | 1 |
| Luciani, G | 1 |
| Lerner, AG | 1 |
| Gelkopf, M | 1 |
| Oyffe, I | 1 |
| Sigal, M | 1 |
| Wylie, AS | 1 |
| Stewart, AM | 1 |
| Waugh, ME | 1 |
| Carroll, KM | 1 |
| Rounsaville, BJ | 3 |
| Diagkogiannis, IA | 1 |
| Schottenfeld, RS | 1 |
| Cox, S | 1 |
| Alcorn, R | 2 |
| Cheskin, LJ | 1 |
| Fudala, PJ | 1 |
| Johnson, RE | 2 |
| Janiri, L | 1 |
| Persico, AM | 1 |
| Serretti, A | 1 |
| Tempesta, E | 1 |
| Ghodse, H | 1 |
| Myles, J | 1 |
| Smith, SE | 1 |
| Azatian, A | 1 |
| Papiasvilli, A | 1 |
| Joseph, H | 1 |
| Dawe, S | 1 |
| Powell, J | 1 |
| Richards, D | 1 |
| Marks, I | 1 |
| Gray, JA | 1 |
| Fishbain, DA | 1 |
| Rosomoff, HL | 1 |
| Cutler, R | 1 |
| Vaupel, DB | 1 |
| Kimes, AS | 1 |
| London, ED | 1 |
| Little, PJ | 1 |
| Price, RR | 1 |
| Hinton, RK | 1 |
| Kuhn, CM | 1 |
| Demaria, PA | 1 |
| Rodgers, C | 1 |
| Braccia, G | 1 |
| Kahn, A | 1 |
| Mumford, JP | 1 |
| Rogers, GA | 1 |
| Beckford, H | 1 |
| Connerney, I | 1 |
| Foltin, RW | 1 |
| Perera, I | 1 |
| Rabinowitz, J | 3 |
| Cohen, H | 3 |
| Tarrasch, R | 1 |
| Kotler, M | 2 |
| Anderson, F | 1 |
| Paluzzi, P | 1 |
| Lee, J | 1 |
| Huggins, G | 1 |
| Svikis, D | 1 |
| Roozen, HG | 1 |
| Deden, AL | 1 |
| Kerkhof, AJ | 1 |
| Vorsteveld, JP | 1 |
| van den Brink, W | 1 |
| Brown, AS | 1 |
| Fleming, PM | 1 |
| Pinelli, A | 1 |
| Trivulzio, S | 1 |
| Spezia, R | 1 |
| Gevirtz, C | 2 |
| Subhedar, DV | 2 |
| Choi, CS | 2 |
| Carnwath, T | 1 |
| Hardman, J | 1 |
| Dashe, JS | 1 |
| Jackson, GL | 1 |
| Olscher, DA | 1 |
| Zane, EH | 1 |
| Wendel, GD | 1 |
| Ingram, SL | 1 |
| Vaughan, CW | 1 |
| Bagley, EE | 1 |
| Connor, M | 1 |
| Christie, MJ | 1 |
| Klein, S | 1 |
| Kaube, H | 1 |
| Kienbaum, P | 2 |
| Peters, J | 2 |
| Gastpar, M | 2 |
| Akhurst, JS | 1 |
| King, VL | 1 |
| Brooner, RK | 1 |
| Kidorf, MS | 1 |
| Stoller, KB | 1 |
| Mirsky, AF | 1 |
| Pozzi, G | 1 |
| Conte, G | 1 |
| De Risio, S | 1 |
| Buntwal, N | 1 |
| Bovill, JG | 1 |
| Ahmadi-Abhari, SA | 1 |
| Akhondzadeh, S | 1 |
| Assadi, SM | 1 |
| Shabestari, OL | 1 |
| Farzanehgan, ZM | 1 |
| Kamlipour, A | 1 |
| Gerra, G | 1 |
| Zaimovic, A | 1 |
| Giusti, F | 1 |
| Di Gennaro, C | 1 |
| Zambelli, U | 1 |
| Gardini, S | 1 |
| Delsignore, R | 1 |
| White, R | 1 |
| Feinmann, C | 1 |
| Heuter, T | 1 |
| Michel, MC | 1 |
| Atias, S | 1 |
| Gowing, LR | 1 |
| Ali, RL | 1 |
| Carreño, JE | 1 |
| Bobes, J | 1 |
| Brewer, C | 1 |
| Alvarez, CE | 1 |
| San Narciso, GI | 1 |
| Bascarán, MT | 1 |
| Sánchez del Río, J | 1 |
| Caillé, S | 1 |
| Espejo, EF | 1 |
| Koob, GF | 1 |
| Stinus, L | 1 |
| Howells, C | 1 |
| Allen, S | 1 |
| Gupta, J | 1 |
| Stillwell, G | 1 |
| Marsden, J | 1 |
| Swift, RM | 1 |
| Stout, RL | 1 |
| Dennison, SJ | 1 |
| Hartmann, F | 1 |
| Poirier, MF | 1 |
| Bourdel, MC | 1 |
| Loo, H | 1 |
| Lecomte, JM | 1 |
| Schwartz, JC | 1 |
| Oliveros, SC | 1 |
| Caballero, L | 1 |
| Iruela, LM | 1 |
| Fraser, AD | 1 |
| Jasinski, DR | 1 |
| Kocher, TR | 1 |
| Beitner, DB | 1 |
| Duman, RS | 1 |
| Nestler, EJ | 1 |
| Fram, DH | 1 |
| Marmo, J | 1 |
| Holden, R | 1 |
| Peachey, JE | 1 |
| Cook, CC | 1 |
| Scannell, TD | 1 |
| Lipsedge, MS | 1 |
| Gil-Ad, I | 1 |
| Bar-Yoseph, J | 1 |
| Smadja, Y | 1 |
| Zohar, M | 1 |
| Laron, Z | 1 |
| Ogawa, N | 1 |
| Hirose, Y | 1 |
| Kuroda, H | 1 |
| Takayama, H | 1 |
| Roehrich, H | 2 |
| Cerri, C | 1 |
| Cocco, E | 1 |
| Rovati, L | 1 |
| Freitas, PM | 1 |
| Rounsaville, B | 1 |
| Charney, D | 1 |
| Gaspari, J | 1 |
| Hogan, I | 1 |
| O'Connor, C | 1 |
| Rozniecki, J | 1 |
| Levadi, DI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome[NCT02851303] | Phase 4 | 61 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Pharmacological Treatment of Neonatal Abstinence Syndrome: Opiate Versus Non-Opiate[NCT01734551] | Phase 4 | 31 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy[NCT03092011] | Phase 4 | 90 participants (Anticipated) | Interventional | 2018-02-21 | Recruiting | ||
| Treatment of Neonatal Abstinence Syndrome: Evaluation of Efficacy of Phenobarbital in Combination With Either Methadone or Diluted Deodorized Tincture of Opium as Stabilizing and Tapering Regiments[NCT01723722] | Phase 4 | 40 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Improving Outcomes in Neonatal Abstinence Syndrome[NCT01958476] | Phase 3 | 117 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Randomized, Active-Control, Double-Blind, Double-Dummy Clinical Trial Comparing Sublingual Buprenorphine And Morphine Solution For The Treatment Of Neonatal Opioid Abstinence Syndrome[NCT01452789] | Phase 3 | 63 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| A Randomized Comparison of Sublingual Buprenorphine to Morphine Sulfate in the Treatment of Neonatal Abstinence Syndrome (NAS)[NCT01708707] | Phase 2 | 29 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Medications Development for Drug Abuse Disorders[NCT01188421] | Phase 1/Phase 2 | 106 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients[NCT00295308] | Phase 1 | 208 participants (Actual) | Interventional | 2005-11-08 | Completed | ||
| A Double-blind Randomised Controlled Clinical Trial of Lofexidine Versus Diazepam in the Management of the Opioid Withdrawal Syndrome During Inpatient Detoxification in Singapore[NCT01675648] | Phase 4 | 112 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Buprenorphine in the Emergency Department: Buprenorphine Versus Clonidine for Opioid Withdrawal[NCT03174067] | Phase 4 | 26 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Examination of Palonosetron and Hydroxyzine Pre-treatment as a Possible Method to Reduce the Objective Signs of Experimentally-induced Acute Opioid Withdrawal in Humans: a Double-blind, Randomized, Placebo-controlled Crossover Study[NCT00661674] | 10 participants (Actual) | Interventional | 2008-04-30 | Completed | |||
| Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain[NCT03396588] | Phase 3 | 120 participants (Actual) | Interventional | 2017-12-07 | Active, not recruiting | ||
| Clinical Outcomes of an Adductor Canal Block Versus Liposomal Bupivacaine in Total Knee Arthroplasty Patients: A Randomized Prospective Study[NCT04086186] | Phase 4 | 60 participants (Actual) | Interventional | 2017-03-22 | Completed | ||
| Long-acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone vs. Buprenorphine[NCT01377610] | Phase 1 | 150 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone: Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder (SWIFT)[NCT04762537] | 415 participants (Actual) | Interventional | 2021-03-16 | Completed | |||
| Time to Detox: A Patient-Centered Comparison of Length of Detoxification Treatment and Time to Naltrexone Maintenance Therapy in Opioid-Dependent Individuals[NCT03678792] | Phase 3 | 0 participants (Actual) | Interventional | 2019-11-15 | Withdrawn (stopped due to Infeasible to conduct at this time.) | ||
| Place of Low-Dose Naltrexone in Opiate Detoxification[NCT00135759] | Phase 2 | 174 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Treatment of Polydrug-Using Opiate Dependents During Withdrawal[NCT00367874] | Phase 4 | 12 participants | Interventional | 2003-02-28 | Completed | ||
| Efficacy of Clonidine in the Treatment of Neonatal Abstinence Syndrome: A Prospective, Double Blind, Randomized Controlled Trial[NCT00510016] | Phase 2 | 80 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Does Preoperative Pain Medication Management Influence Surgical Outcomes in Spinal Fusion: A Randomized Controlled Study[NCT04095624] | 84 participants (Anticipated) | Interventional | 2019-09-09 | Recruiting | |||
| A Pilot Randomized Comparative Effectiveness Clinical Trial of Buprenorphine vs. Methadone for the Treatment of Opioid Dependence in Pregnancy.[NCT03098407] | 55 participants (Actual) | Interventional | 2017-04-20 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assessed through chart review of discharge summary documentation of method of infant feeding at time of discharge (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 5 |
| Methadone | 5 |
Number of days in hospital after birth (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | days (Mean) |
|---|---|
| Morphine | 17.9 |
| Methadone | 16.1 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | days (Mean) |
|---|---|
| Morphine | 14.7 |
| Methadone | 12.8 |
clonidine (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 1 |
| Methadone | 0 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 11 |
| Methadone | 6 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 0 |
| Methadone | 3 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | morphine equivalents mg (Mean) |
|---|---|
| Morphine | 9.86 |
| Methadone | 33.0 |
Total number days of treatment (NCT01734551)
Timeframe: 120 days
| Intervention | days (Median) |
|---|---|
| Morphine | 39 |
| Clonidine | 27 |
Scores obtained Bayley Scales of Infant and Toddler Development Third Edition in the developmental domains of motor, cognitive, and language. This tool for measures of motor, cognitive and language development is a series of standardized measurements and for each domain, the standardized scores have a mean of 100 and standard deviation of 15. Scores below 1 standard deviation (= or less than 84) is considered below normal. Scores above 1 standard deviation (over 115) represent higher than normal functioning in each domain The score for each domain (motor, cognitive, and language functioning) represents the full-scale score (NCT01734551)
Timeframe: 1 year of life
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Bayley III motor | Cognitive | Language total | Language Receptive | Language Expressive | |
| Clonidine | 95.8 | 93.3 | 95.8 | 95.0 | 99.2 |
| Morphine | 97.6 | 92.9 | 98.0 | 101.1 | 100.0 |
Mean of total Finnegan Scores obtained every 3 hours on days 2, 7, and 14 following start of treatment; A score is a number representing the total score or sum from 21 items or symptoms or manifestations of opiate withdrawal in newborn infants. The total score ranges from 0 to 43. Reference: 1. Finnegan LP, Connaughton JF, Jr., Kron RE, et al. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975;2(1-2):141-58. Although normal newborn may manifest mild symptoms that will give scores in the range of 0 to 7. A score of 8 consecutively obtained times 3 indicate that infant will benefit from treatment, in this study morphine or clonidine. A decrease in scores especially to less than 8 is suggestive of a good response to treatment. (NCT01734551)
Timeframe: 14 days
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Finnegan scores day 2 of treatment | Finnegan scores day 7 of treatment | Finnegan scores day 14 of treatment | |
| Clonidine | 8.5 | 5.7 | 6.7 |
| Morphine | 7.5 | 6.6 | 7.1 |
The summary scores from the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) give a measure of infant neurobehavior in the following areas (score range): habituation (1-9), regulation (2.20-7.50), attention (1.29 -8.4), Handling (0 - 1), quality of movement (1.20 - 6.20), Non-optimal reflexes (0-12), Asymmetric reflexes (0-7), arousal (2.43 - 6.67), hypertonicity (0- 8), hypotonicity (0 - 5.0), excitability (0-11), lethargy (0 - 11.0). and stress/abstinence (0. - 0.57). A higher score for each item means a higher level of the construct. For example, a higher score for hypertonicity means the infant is more hypertonic and higher score on hypotonicity means the infant is more hypotonic. No cut-off score published for normal or abnormal behavioral performance. Reference: Lester BM et al. Summary Statistics of Neonatal Intensive Care Unit Network Neurobehavioral Scale Scores From the Maternal Lifestyle Study: A Quasinormative Sample, in Pediatrics 2004; 113,668. (NCT01734551)
Timeframe: 5-10 days after treatment starts
| Intervention | scores on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Attention | Handling | Quality of movement | Regulation | Non-optimal reflexes | Asymmetric reflexes | Stress/abstinence | Arousal | Hypertonicity | Hypotonicity | Excitability | Lethargy | |
| Clonidine | 4.51 | 0.42 | 4.92 | 5.26 | 4.13 | 0.00 | 0.08 | 3.95 | 0.25 | 0.19 | 2.38 | 5.13 |
| Morphine | 5.06 | 0.36 | 4.77 | 5.2 | 3.73 | 0.20 | 0.07 | 3.91 | 0.40 | 0.13 | 2.6 | 3.6 |
Up to 12 months (NCT01723722)
Timeframe: Up to 12 months
| Intervention | days (Mean) |
|---|---|
| Deodorized Tincture Opium After Phenobarbital for Withdrawal | 19.1 |
| Methadone After Phenobarbital for Withdrawal | 17.7 |
Average head circumference growth outcome at 18 month follow-up visit. (NCT01958476)
Timeframe: 18 month follow-up visit
| Intervention | cm (Mean) |
|---|---|
| Methadone | 47.8 |
| Neonatal Morphine Solution | 48.2 |
Average length (cm) at 18 month follow-up visit. (NCT01958476)
Timeframe: 18 month follow-up visit
| Intervention | cm (Mean) |
|---|---|
| Methadone | 82.1 |
| Neonatal Morphine Solution | 81.7 |
Growth outcome weight (lbs) depicted as difference in averaged weights from birth to 18 month follow-up visit. Standard deviations were averaged between birth and 18 mo time points. (NCT01958476)
Timeframe: Birth to 18 month follow-up visit
| Intervention | lbs (Mean) |
|---|---|
| Methadone | 19.1 |
| Neonatal Morphine Solution | 18.7 |
Participants were monitored for the duration of their hospitalization, an expected mean of 22 days. (NCT01958476)
Timeframe: Participants will be monitored during their entire hospitalization, expected mean 22 days.
| Intervention | days (Mean) |
|---|---|
| Methadone | 21.8 |
| Neonatal Morphine Solution | 23.2 |
Participants were monitored for the duration of their hospitalization attributable to NAS only. (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, expected mean 22 days.
| Intervention | days (Mean) |
|---|---|
| Methadone | 18.9 |
| Neonatal Morphine Solution | 21.1 |
Total number of days infant treated with replacement opioids while admitted to the hospital. (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization.
| Intervention | days (Mean) |
|---|---|
| Methadone | 14.7 |
| Neonatal Morphine Solution | 16.6 |
"One Finnegan score ≥12, or two consecutive scores ≥8 affirms the requirement for pharmacological treatment or increasing treatment dosage. If the infant continued to have two consecutive Finnegan Scores ≥8 two times consecutively, or one ≥12, the dose was increased to the next level. (Level I: 0.3 mg/kg/day) (Level II: 0.5 mg/kg/day) (Level III: 0.7 mg/kg/day)~A higher Finnegan score indicates greater severity of NAS (min 0, max 50)." (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, an average of 22 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Methadone | 22 |
| Neonatal Morphine Solution | 28 |
Number of infants treated with a second medication following protocol, phenobarbital. If the Finnegan Score remained elevated (still scored ≥8 two times consecutively, or still scored once ≥12) despite increasing to a predetermined maximal opioid dose (methadone or morphine), phenobarbital was administered (20-mg/kg loading dose followed by 4-5 mg/kg daily). (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, an average of 22 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Methadone | 10 |
| Neonatal Morphine Solution | 17 |
The Bayley Scales of Infant and Toddler Development (BSID-III) assesses the development of infants and children (1-42 months) through a series of developmental play tasks, identifying children with developmental delay. Raw scores of completed items are summarized within three distinct scale scores (Cognitive Scale, Language Scale, Motor Scale). Scale scores are each converted to composite scores to determine the child's performance compared with scores of age-matched children of typical development (percentile rank). A higher composite score indicates more ideal developmental outcome (range 40-160). At 18 month follow-up visit, participants were assessed using the BSID-III for cognitive, language and motor scale composite score outcomes. (NCT01958476)
Timeframe: Assessment at 18 month follow-up visit
| Intervention | scores on a scale (Composite) (Mean) | ||
|---|---|---|---|
| Cognitive Composite | Language Composite | Motor Composite | |
| Methadone | 100.1 | 96.0 | 103.6 |
| Neonatal Morphine Solution | 98.1 | 94.2 | 99.1 |
This endpoint will compare length of stay in the hospital (in days) using sublingual buprenorphine or morphine solution. (NCT01452789)
Timeframe: Duration of hospital stay is an expected average of 5 weeks.
| Intervention | days (Median) |
|---|---|
| Sublingual Buprenorphine | 21 |
| Oral Morphine | 33 |
This endpoint will compare length of treatment (in days) using sublingual buprenorphine or oral morphine solution. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | days (Median) |
|---|---|
| Sublingual Buprenorphine | 15 |
| Oral Morphine | 28 |
Adverse events will be collected, graded by severity, and assessed for causality referent to study drug. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sublingual Buprenorphine | 7 |
| Oral Morphine | 8 |
This endpoint will compare requirement number of patients who require use of supplemental phenobarbital. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | participants (Number) |
|---|---|
| Sublingual Buprenorphine | 5 |
| Oral Morphine | 7 |
Outcomes represent mean peak withdrawal as rated on the Clinical Opiate Withdrawal Scale (COWS) total score. Withdrawal was collected 7 times daily and daily peak values were identified for each participant and averaged together as a function of group. Primary outcomes were mean peak results from the 7-day taper period and first 7 days post-taper. The COWS is an 11-item observer-rated measure of opioid withdrawal severity. Items are rated on individual Likert scales and the total score range is 0-47. Higher values indicate more severe withdrawal. (NCT01188421)
Timeframe: 14 days total
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Taper Day 1 | Taper Day 2 | Taper Day 3 | Taper Day 4 | Taper Day 5 | Taper Day 6 | Taper Day 7 | Post Taper Day 1 | Post Taper Day 2 | Post Taper Day 3 | Post Taper Day 4 | Post Taper Day 5 | Post Taper Day 6 | Post Taper Day 7 | |
| Buprenorphine | 7.79 | 6.16 | 4.76 | 4.21 | 4.31 | 4.06 | 3.51 | 4.82 | 5.62 | 6.23 | 5.49 | 5.87 | 4.91 | 4.91 |
| Clonidine | 8.28 | 8.00 | 5.85 | 4.70 | 3.32 | 3.57 | 3.86 | 3.27 | 4.09 | 3.68 | 3.82 | 3.27 | 2.91 | 2.41 |
| Tramadol ER | 8.41 | 6.10 | 3.77 | 4.25 | 3.25 | 3.39 | 3.69 | 3.36 | 4.48 | 3.28 | 3.13 | 2.75 | 2.57 | 2.30 |
"The OOWS is a 13-item instrument documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. Maximum score possible = 13, minimum score possible = 0. T=15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~OOWS scores at T=180 is the primary outcome measure of the study compared with baseline OOWS scores at T=-30 (30 minutes prior to study medication administration). Reported time frames are in relation to time past since administration of study medications.~Mean post-Naloxone OOWS scores (+/- SEM) were determined for pretreatment groups" (NCT00661674)
Timeframe: Change from baseline in OOWS score at 180 minutes (15 minutes post naloxone administration)
| Intervention | units on a scale (OOWS Scale) (Mean) |
|---|---|
| Placebo | 3.5 |
| Palonosetron | 1.0 |
| Palonosetron + Hydroxyzine | 0 |
"The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. 15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~The highest score possible (64) would indicate that the individual was experiencing every symptom of opioid withdrawal to the fullest extent possible while the lowest score (0) would indicate that the individual was not experiencing any symptoms of opioid withdrawal.~Mean post-naloxone SOWS scores (+/- SEM) were computed for pretreatment groups: Placebo, palonosetron, and palonosetron with hydroxyzine" (NCT00661674)
Timeframe: Change from baseline in SOWS score at 180 minutes (15 minutes post naloxone administration)
| Intervention | units on a scale (SOWS Scale) (Mean) |
|---|---|
| Placebo | 6.0 |
| Palonosetron | 4.0 |
| Palonosetron + Hydroxyzine | 3.5 |
Time to receipt of first injection of XR-NTX from day of admission for participants that receive first injection of XR-NTX. (NCT04762537)
Timeframe: Induction Phase: 1-30 days
| Intervention | Days (Mean) |
|---|---|
| Standard Induction Method | 14.5 |
| Rapid Induction Method | 7.0 |
The primary goal of the study is to show RP is non-inferior to SP XR-NTX induction method. (NCT04762537)
Timeframe: Induction Phase: 1-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Induction Method | 68 |
| Rapid Induction Method | 141 |
44 reviews available for clonidine and Addiction, Opioid
| Article | Year |
|---|---|
Efficacy and safety of tramadol in the treatment of opioid withdrawal: A meta-analysis of randomized controlled trials.
Topics: Bayes Theorem; Buprenorphine; Clonidine; Humans; Methadone; Narcotics; Opioid-Related Disorders; Ran | 2023 |
A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms.
Topics: Analgesics, Opioid; Clonidine; Humans; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2020 |
Lofexidine: A Novel Treatment Option for Opioid Withdrawal Symptoms.
Topics: Analgesics, Opioid; Clonidine; Humans; Opioid-Related Disorders; United States | 2020 |
Sedatives for opioid withdrawal in newborn infants.
Topics: Bias; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn; Narcoti | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid antagonists with minimal sedation for opioid withdrawal.
Topics: Adrenergic alpha-Agonists; Clonidine; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Non-Random | 2017 |
Pharmacological therapies for management of opium withdrawal.
Topics: Amantadine; Amines; Baclofen; Buprenorphine; Clonidine; Cyclohexanecarboxylic Acids; Gabapentin; gam | 2018 |
Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal.
Topics: Adult; Clonidine; Humans; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Tria | 2019 |
Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome.
Topics: Analgesia, Obstetrical; Analgesics; Analgesics, Opioid; Breast Feeding; Buprenorphine; Buprenorphine | 2019 |
Detoxification treatments for opiate dependent adolescents.
Topics: Adolescent; Buprenorphine; Clonidine; Humans; Maintenance Chemotherapy; Naloxone; Naltrexone; Narcot | 2014 |
Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes?
Topics: Adrenergic alpha-2 Receptor Agonists; Alcoholism; Clonidine; Dexmedetomidine; Humans; Opioid-Related | 2014 |
Reduction of opiate withdrawal symptoms with use of clonidine in a county jail.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Clonidine; Female; Humans; Male; Middle Aged; Opioid-Re | 2015 |
Alpha₂-adrenergic agonists for the management of opioid withdrawal.
Topics: Acute Disease; Adrenergic alpha-2 Receptor Agonists; Clonidine; Controlled Clinical Trials as Topic; | 2016 |
Clonidine Use in Psychiatry: Panacea or Panache.
Topics: Animals; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Clonidine; Humans; Men | 2016 |
Update on pharmacotherapy for treatment of opioid use disorder.
Topics: Adrenergic alpha-2 Receptor Agonists; Buprenorphine; Clonidine; Combined Modality Therapy; Humans; M | 2016 |
Buprenorphine for managing opioid withdrawal.
Topics: Acute Disease; Buprenorphine; Clonidine; Female; Humans; Male; Methadone; Narcotic Antagonists; Opia | 2017 |
Detoxification treatments for opiate dependent adolescents.
Topics: Adolescent; Buprenorphine; Clonidine; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disor | 2009 |
Buprenorphine for the management of opioid withdrawal.
Topics: Acute Disease; Buprenorphine; Clonidine; Humans; Narcotic Antagonists; Opioid-Related Disorders; Ran | 2009 |
Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adult; Child; Clonidine; Critical I | 2009 |
Opioid antagonists with minimal sedation for opioid withdrawal.
Topics: Adrenergic alpha-Agonists; Clinical Trials as Topic; Clonidine; Humans; Naloxone; Naltrexone; Narcot | 2009 |
Lofexidine, an {alpha}2-receptor agonist for opioid detoxification.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Animals; Clinical Trials as Topic; | 2010 |
A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Buprenorphine; Clonidine; Data Inte | 2010 |
The pharmacological treatment of opioid addiction--a clinical perspective.
Topics: Adrenergic Agonists; Analgesics, Opioid; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans | 2010 |
Sedatives for opiate withdrawal in newborn infants.
Topics: Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn; Narcotics; Ne | 2010 |
[α2-Agonists during withdrawal].
Topics: Adrenergic alpha-2 Receptor Agonists; Alcoholism; Clonidine; Humans; Opioid-Related Disorders; Subst | 2011 |
Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.
Topics: Adrenergic alpha-2 Receptor Agonists; Buprenorphine; Clinical Protocols; Clonidine; Drug Administrat | 2012 |
Sedatives for opiate withdrawal in newborn infants.
Topics: Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn; Neonatal Abst | 2002 |
Buprenorphine for the management of opioid withdrawal.
Topics: Acute Disease; Buprenorphine; Clonidine; Humans; Narcotic Antagonists; Opioid-Related Disorders; Ran | 2004 |
Sedatives for opiate withdrawal in newborn infants.
Topics: Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn; Neonatal Abst | 2005 |
Opioid antagonists with minimal sedation for opioid withdrawal.
Topics: Adrenergic alpha-Agonists; Clinical Trials as Topic; Clonidine; Humans; Naloxone; Naltrexone; Narcot | 2006 |
Buprenorphine for the management of opioid withdrawal.
Topics: Acute Disease; Buprenorphine; Clonidine; Humans; Narcotic Antagonists; Opioid-Related Disorders; Ran | 2006 |
Opiate addiction in China: current situation and treatments.
Topics: Buprenorphine; China; Clonidine; Drugs, Chinese Herbal; HIV Infections; Humans; Methadone; Naltrexon | 2006 |
The sequential use of clonidine and naltrexone in the treatment of opiate addicts.
Topics: Adult; Baclofen; Clonidine; Drug Therapy, Combination; Electric Stimulation Therapy; Endorphins; Eth | 1984 |
Lofexidine and opioid withdrawal.
Topics: Antihypertensive Agents; Clonidine; Humans; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1995 |
Opiate detoxification protocols. A clinical manual.
Topics: Administration, Cutaneous; Clinical Protocols; Clonidine; Codeine; Female; Humans; Male; Methadone; | 1993 |
Opiate detoxification protocols. A clinical manual.
Topics: Administration, Cutaneous; Clinical Protocols; Clonidine; Codeine; Female; Humans; Male; Methadone; | 1993 |
Opiate detoxification protocols. A clinical manual.
Topics: Administration, Cutaneous; Clinical Protocols; Clonidine; Codeine; Female; Humans; Male; Methadone; | 1993 |
Opiate detoxification protocols. A clinical manual.
Topics: Administration, Cutaneous; Clinical Protocols; Clonidine; Codeine; Female; Humans; Male; Methadone; | 1993 |
Opiate addiction and the locus coeruleus. The clinical utility of clonidine, naltrexone, methadone, and buprenorphine.
Topics: Animals; Buprenorphine; Clonidine; Humans; Locus Coeruleus; Methadone; Naltrexone; Opioid-Related Di | 1993 |
Nitric oxide synthase inhibitors. Preclinical studies of potential use for treatment of opioid withdrawal.
Topics: Adrenergic alpha-Agonists; Animals; Arginine; Blood Pressure; Clonidine; Depression, Chemical; Enzym | 1995 |
Compliance to naltrexone treatment after ultra-rapid opiate detoxification: an open label naturalistic study.
Topics: Anesthesia, General; Clonidine; Follow-Up Studies; Humans; Israel; Male; Naltrexone; Narcotic Antago | 1997 |
Lofexidine for opiate detoxification: review of recent randomised and open controlled trials.
Topics: Clonidine; Humans; Methadone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled | 1999 |
Alpha2-adrenergic agonists in opioid withdrawal.
Topics: Adrenergic alpha-Agonists; Clonidine; Confidence Intervals; Controlled Clinical Trials as Topic; Hum | 2002 |
[Clonidine-naltrexone: a new technic for the detoxification of opiate addicts].
Topics: Clonidine; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotics; Opioid-Related Disor | 1990 |
Clinical toxicology of drugs used in the treatment of opiate dependency.
Topics: Buprenorphine; Clonidine; Humans; Methadone; Methadyl Acetate; Naltrexone; Opioid-Related Disorders | 1990 |
Clonidine.
Topics: Alcoholism; Clonidine; Humans; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1987 |
Narcotic withdrawal in the emergency department.
Topics: Clonidine; Emergency Service, Hospital; Endorphins; Humans; Methadone; Narcotics; Nervous System Dis | 1985 |
60 trials available for clonidine and Addiction, Opioid
| Article | Year |
|---|---|
Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Administration, Oral; Adolescent; Adult; Chemoprevention; Clonidine; Craving; Double-Blind Method; D | 2019 |
A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.
Topics: Adult; Analgesics, Opioid; Animals; Clonidine; Double-Blind Method; Female; Humans; Inpatients; Male | 2017 |
Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
Topics: Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Clonidine; Craving; Double-Blind Metho | 2017 |
Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Topics: Adult; Analgesics; Analgesics, Opioid; Buprenorphine; Clonidine; Delayed-Action Preparations; Double | 2017 |
Using ecological momentary assessment to examine the relationship between craving and affect with opioid use in a clinical trial of clonidine as an adjunct medication to buprenorphine treatment.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Affect; Buprenorphine; Clonidine; Craving; Double-Blind | 2018 |
Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: A double-blind randomized clinical trial in Singapore.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Clonidine; Craving; Diazepam; Double-Blind Method; Fema | 2018 |
Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.
Topics: Adult; Analgesics; Buprenorphine; Clonidine; Cluster Analysis; Double-Blind Method; Female; Humans; | 2020 |
An open-label randomized trial of intramuscular olanzapine versus oral clonidine for symptomatic treatment of opioid withdrawal in the emergency department.
Topics: Administration, Oral; Adult; Aged; Clonidine; Female; Humans; Injections, Intramuscular; Male; Middl | 2019 |
Buprenorphine in the emergency department: Randomized clinical controlled trial of clonidine versus buprenorphine for the treatment of opioid withdrawal.
Topics: Adult; Buprenorphine; Clonidine; Emergency Service, Hospital; Female; Humans; Male; Narcotic Antagon | 2019 |
Morphine versus clonidine for neonatal abstinence syndrome.
Topics: Analgesics; Arousal; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2015 |
Morphine versus clonidine for neonatal abstinence syndrome.
Topics: Analgesics; Arousal; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2015 |
Morphine versus clonidine for neonatal abstinence syndrome.
Topics: Analgesics; Arousal; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2015 |
Morphine versus clonidine for neonatal abstinence syndrome.
Topics: Analgesics; Arousal; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2015 |
Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment.
Topics: Adult; Analgesics; Buprenorphine; Clonidine; Craving; Double-Blind Method; Drug Therapy, Combination | 2015 |
Baseline characteristics of patients predicting suitability for rapid naltrexone induction.
Topics: Administration, Oral; Adult; Buprenorphine; Clonidine; Delayed-Action Preparations; Drug Therapy, Co | 2015 |
Is There a Benefit for Liposomal Bupivacaine Compared to a Traditional Periarticular Injection in Total Knee Arthroplasty Patients With a History of Chronic Opioid Use?
Topics: Aged; Amides; Analgesics, Opioid; Anesthetics, Local; Arthroplasty, Replacement, Knee; Bupivacaine; | 2016 |
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Behavior Therapy; Buprenorphine; Clonidine | 2017 |
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Behavior Therapy; Buprenorphine; Clonidine | 2017 |
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Behavior Therapy; Buprenorphine; Clonidine | 2017 |
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Behavior Therapy; Buprenorphine; Clonidine | 2017 |
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Behavior Therapy; Buprenorphine; Clonidine | 2017 |
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Behavior Therapy; Buprenorphine; Clonidine | 2017 |
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Behavior Therapy; Buprenorphine; Clonidine | 2017 |
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Behavior Therapy; Buprenorphine; Clonidine | 2017 |
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Behavior Therapy; Buprenorphine; Clonidine | 2017 |
Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Anxiety; Buprenorphine; Clonidine; Data Interpretation, Stat | 2009 |
Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Adult; Biological Availability; Chromatography, Liq | 2008 |
Intensity of opiate withdrawal in relation to the 825C>T polymorphism of the G-protein beta 3 subunit gene.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Clonidine; | 2009 |
Electrocardiographic effects of lofexidine and methadone coadministration: secondary findings from a safety study.
Topics: Adult; Clonidine; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Fema | 2009 |
Outpatient versus inpatient opioid detoxification: a randomized controlled trial.
Topics: Analgesics, Opioid; Clonidine; Female; Heroin; Heroin Dependence; Humans; Inpatients; Male; Methadon | 2011 |
The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Clonidine; Disease Management; Dose-Respons | 2012 |
A comparison of suboxone and clonidine treatment outcomes in opiate detoxification.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Buprenorphine; Buprenorphine, Naloxone Drug | 2012 |
Clonidine and yohimbine in opioid-dependent humans responding under a naloxone novel-response discrimination procedure.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adult; Clonidine; Discrimination, Psycholog | 2003 |
A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.
Topics: Adult; Buprenorphine; Clonidine; Female; Humans; Inactivation, Metabolic; Male; Naloxone; Narcotic A | 2005 |
Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
Topics: Administration, Cutaneous; Adolescent; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Beha | 2005 |
A comparison of buprenorphine and lofexidine for community opiate detoxification: results from a randomized controlled trial.
Topics: Adolescent; Adult; Buprenorphine; Clonidine; Community Mental Health Services; Female; Humans; Male; | 2005 |
In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Clonidine; Cohort Studies; Double- | 2007 |
Treatment of polydrug-using opiate dependents during withdrawal: towards a standardisation of treatment.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Buprenorphine; Carbamazepine; Clonidi | 2006 |
Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.
Topics: Adult; Behavior, Addictive; Clonidine; Cues; Double-Blind Method; Drug Therapy, Combination; Female; | 2007 |
Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.
Topics: Adrenergic alpha-Agonists; Adult; Analysis of Variance; Clonidine; Drug Therapy, Combination; Female | 2007 |
The role of the National Institute on Drug Abuse in the development of naltrexone.
Topics: Aftercare; Animals; Carcinogens; Clinical Trials as Topic; Clonidine; Drug Administration Schedule; | 1984 |
Clonidine versus methadone for opiate detoxification.
Topics: Clinical Trials as Topic; Clonidine; Humans; Inactivation, Metabolic; Methadone; Naltrexone; Opioid- | 1980 |
Clinical utility of clonidine in opiate withdrawal: a study of 100 patients.
Topics: Blood Pressure; Clinical Trials as Topic; Clonidine; Humans; Methadone; Naloxone; Norepinephrine; Op | 1981 |
Opiate withdrawal using lofexidine, a clonidine analogue with fewer side effects.
Topics: Adult; Ambulatory Care; Antihypertensive Agents; Clinical Trials as Topic; Clonidine; Humans; Male; | 1983 |
[Withdrawal of drug addicts from opiates using Limoge-type electrotherapy. Evaluation of 400 treatments].
Topics: Adolescent; Adult; Clinical Trials as Topic; Clonidine; Double-Blind Method; Electric Stimulation Th | 1982 |
Clonidine and naltrexone. A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy.
Topics: Adult; Blood Pressure; Clonidine; Double-Blind Method; Drug Administration Schedule; Female; Heart R | 1982 |
Home-based inpatient treatment vs. outpatient day clinic treatment: a preliminary report in opiate-dependent patients.
Topics: Adult; Ambulatory Care; Clonidine; Day Care, Medical; Follow-Up Studies; Home Care Services; Humans; | 1995 |
Primary care-based ambulatory opioid detoxification: the results of a clinical trial.
Topics: Adolescent; Adult; Ambulatory Care; Chi-Square Distribution; Clonidine; Cohort Studies; Drug Adminis | 1995 |
A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids.
Topics: Adult; Baltimore; Buprenorphine; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; D | 1994 |
Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Clonidine; Dose-Response Relationship, Drug; Double-Blind | 1994 |
Clonidine is not a useful adjunct to methadone gradual detoxification in opioid addiction.
Topics: Adolescent; Adult; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administra | 1994 |
Does post-withdrawal cue exposure improve outcome in opiate addiction? A controlled trial.
Topics: Adult; Behavior Therapy; Clonidine; Cues; Female; Follow-Up Studies; Hospitalization; Humans; Male; | 1993 |
Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital.
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; | 1997 |
A protocol to switch high-dose, methadone-maintained subjects to buprenorphine.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Buprenorphine; Clonidine; Cocaine; Drug Administration Schedule | 1997 |
Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Clonidine; Dose-Response Relationship, Drug; D | 1998 |
Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal.
Topics: Adrenergic alpha-Agonists; Adult; Ambulatory Care; Blood Pressure; Chi-Square Distribution; Clonidin | 1998 |
Alternative strategies of opiate detoxification: evaluation of the so-called ultra-rapid detoxification.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Anesthesia; Clonidine; Female; Humans; Male; Methadone | 1998 |
Combined use of trazodone-naltrexone versus clonidine-naltrexone in rapid withdrawal from methadone treatment. A comparative inpatient study.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Analysis of Variance; Clonidine; Drug Therapy, Combina | 2000 |
Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification.
Topics: Adult; Blood Pressure; Clonidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dr | 2000 |
Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial.
Topics: Adult; Analgesics; Baclofen; Clonidine; Double-Blind Method; Humans; Male; Muscle Relaxants, Central | 2001 |
Lofexidine versus clonidine in rapid opiate detoxification.
Topics: Adult; Analysis of Variance; Clonidine; Double-Blind Method; Humans; Inactivation, Metabolic; Male; | 2001 |
Sympathetic neural activation evoked by mu-receptor blockade in patients addicted to opioids is abolished by intravenous clonidine.
Topics: Adrenergic alpha-Agonists; Adult; Anesthesia; Catecholamines; Clonidine; Electrocardiography; Hemody | 2002 |
24-Hour opiate detoxification and antagonist induction at home--the 'Asturian method': a report on 1368 procedures.
Topics: Administration, Oral; Adult; Aftercare; Anti-Anxiety Agents; Benzodiazepines; Clonidine; Drug Implan | 2002 |
Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Clonidine; Double-Blind Method; Humans; Male; | 2002 |
Comparison of acetorphan with clonidine for opiate withdrawal symptoms.
Topics: Adolescent; Adult; Clonidine; Double-Blind Method; Female; Heroin; Humans; Male; Narcotics; Neprilys | 1991 |
Clonidine in morphine withdrawal. Differential effects on signs and symptoms.
Topics: Clonidine; Dose-Response Relationship, Drug; Heroin Dependence; Hospitalization; Humans; Hydromorpho | 1985 |
Another trial that failed.
Topics: Attitude of Health Personnel; Clinical Trials as Topic; Clonidine; Double-Blind Method; Humans; Opio | 1988 |
Effect of clonidine on plasma beta-endorphin, cortisol and growth hormone secretion in opiate-addicted subjects.
Topics: Adolescent; Adult; beta-Endorphin; Clinical Trials as Topic; Clonidine; Endorphins; Female; Growth H | 1985 |
Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine- and methadone-assisted withdrawal.
Topics: Adult; Ambulatory Care; Clinical Trials as Topic; Clonidine; Female; Follow-Up Studies; Humans; Male | 1985 |
Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts.
Topics: Adult; Clinical Trials as Topic; Clonidine; Double-Blind Method; Female; Humans; Male; Methadone; Op | 1985 |
Clonidine in outpatient detoxification from methadone maintenance.
Topics: Adult; Ambulatory Care; Clonidine; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Diso | 1985 |
137 other studies available for clonidine and Addiction, Opioid
| Article | Year |
|---|---|
Pharmacological Management of Heroin Withdrawal Syndrome: A Century of Expert Opinions in Cecil Textbook of Medicine.
Topics: Analgesics, Opioid; Buprenorphine; Clonidine; Expert Testimony; Heroin; Humans; Methadone; Narcotics | 2022 |
Identifying Clinically Relevant Drug-Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal Detection.
Topics: Baclofen; Bayes Theorem; Benzodiazepines; Buprenorphine; Clonidine; Drug Interactions; Fluconazole; | 2022 |
Impact of dexmedetomidine in conjunction with a weaning protocol on post-surgical opioid use in a neonatal intensive care unit.
Topics: Acetaminophen; Analgesics, Opioid; Clonidine; Dexmedetomidine; Humans; Infant, Newborn; Intensive Ca | 2023 |
Ropivacaine-Epinephrine-Clonidine-Ketorolac Cocktail as a Local Anesthetic for Lumbar Decompression Surgery: A Single Institutional Experience.
Topics: Adolescent; Adult; Analgesics, Opioid; Anesthetics, Local; Clonidine; Decompression; Epinephrine; GP | 2023 |
Multimodal Analgesia Bundle and Postoperative Opioid Use Among Patients Undergoing Colorectal Surgery.
Topics: Agnosia; Analgesia; Analgesics, Opioid; Clonidine; Cohort Studies; Colorectal Surgery; Female; Gabap | 2023 |
Multimodal intrathecal analgesia (MITA) with morphine for reducing postoperative opioid use and acute pain following hepato-pancreato-biliary surgery: A multicenter retrospective study.
Topics: Acute Pain; Analgesia; Analgesics, Opioid; Bupivacaine; Clonidine; Humans; Morphine; Opioid-Related | 2023 |
Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome.
Topics: Adult; Analgesics, Opioid; Animals; Buprenorphine, Naloxone Drug Combination; Clonidine; Female; Hum | 2020 |
Validation and characterization of oxycodone physical dependence in C57BL/6J mice.
Topics: Analgesics; Analgesics, Opioid; Animals; Behavior, Animal; Clonidine; Disease Models, Animal; Dose-R | 2021 |
A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
Topics: Adult; Amines; Analgesics, Opioid; Buprenorphine; Clonidine; Counseling; Cyclohexanecarboxylic Acids | 2018 |
Use of epidural clonidine for the management of analgesia in the opioid addicted parturient on buprenorphine maintenance therapy: an observational study.
Topics: Adrenergic alpha-Agonists; Adult; Analgesia, Epidural; Analgesia, Obstetrical; Buprenorphine; Cathet | 2018 |
FDA approves nonopioid medication for managing opioid withdrawal.
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Clonidine; Drug Approval; Humans; Narcotic | 2018 |
Lofexidine (Lucemyra) for opioid withdrawal.
Topics: Clonidine; Drug Approval; Drug Interactions; Humans; Narcotic Antagonists; Opioid-Related Disorders; | 2018 |
Management of opioid withdrawal symptoms.
Topics: Adrenergic alpha-2 Receptor Agonists; Buprenorphine; Clonidine; Humans; Methadone; Narcotic Antagoni | 2018 |
Expanded table: Some drugs for management of opioid withdrawal symptoms.
Topics: Adrenergic alpha-2 Receptor Agonists; Buprenorphine; Clonidine; Humans; Methadone; Narcotic Antagoni | 2018 |
Novel Withdrawal Symptoms of a Neonate Prenatally Exposed to a Fentanyl Analog.
Topics: Anticonvulsants; Clonidine; Female; Fentanyl; Humans; Infant, Newborn; Levetiracetam; Methadone; Myo | 2019 |
Lofexidine (Lucemyra) for Treatment of Opioid Withdrawal Symptoms.
Topics: Adrenergic alpha-2 Receptor Agonists; Clonidine; Dose-Response Relationship, Drug; Humans; Opioid-Re | 2019 |
Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report.
Topics: Adult; Antidiarrheals; Antiemetics; Antipruritics; Buprenorphine; Clonidine; Deprescriptions; Drug S | 2019 |
Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Animals; Behavior, Animal; Choice Behavior | 2019 |
Racial association and pharmacotherapy in neonatal opioid withdrawal syndrome.
Topics: Analgesics; Black or African American; Clonidine; Drug Therapy, Combination; Female; Humans; Infant, | 2019 |
The preclinical discovery of lofexidine for the treatment of opiate addiction.
Topics: Animals; Clonidine; Drug Discovery; Humans; Narcotic Antagonists; Opioid-Related Disorders | 2014 |
A New Role for Clonidine in Addictions: Catching Relapses Before They Happen.
Topics: Analgesics; Buprenorphine; Clonidine; Craving; Female; Humans; Male; Narcotic Antagonists; Opioid-Re | 2015 |
Psychometric evaluation of the 10-item Short Opiate Withdrawal Scale-Gossop (SOWS-Gossop) in patients undergoing opioid detoxification.
Topics: Adult; Clonidine; Factor Analysis, Statistical; Female; Humans; Male; Narcotic Antagonists; Opioid-R | 2016 |
Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.
Topics: Adult; Amines; Analgesics, Opioid; Buprenorphine; Clonidine; Cyclohexanecarboxylic Acids; Female; Ga | 2017 |
Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients.
Topics: Administration, Oral; Adult; Analysis of Variance; Area Under Curve; Chromatography, Liquid; Clonidi | 2009 |
Case scenario: self-extraction of intrathecal pump medication with a concomitant intrathecal granulomatous mass.
Topics: Acetaminophen; Administration, Cutaneous; Adult; Analgesics; Analgesics, Non-Narcotic; Analgesics, O | 2011 |
A nonopioid procedure for outpatient opioid detoxification.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Benzhydryl Compounds; Central Nervous Syste | 2011 |
Improvement in psychopathology among opioid-dependent adolescents during behavioral-pharmacological treatment.
Topics: Adolescent; Affective Symptoms; Ambulatory Care; Behavior Therapy; Buprenorphine; Clonidine; Combine | 2011 |
Opioid dependence.
Topics: Buprenorphine; Clonidine; Evidence-Based Medicine; Humans; Inactivation, Metabolic; Methadone; Nalox | 2012 |
Topiramate in opiate withdrawal.
Topics: Adrenergic alpha-Agonists; Adult; Anticonvulsants; Clonidine; Female; Fructose; Heroin Dependence; H | 2002 |
The effect of clonidine on gastrointestinal side effects associated with ultra-rapid opioid detoxification.
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Diarrhea; Female; Gastrointestinal Diseases; Humans; Hy | 2003 |
Opiate withdrawal induces Narp in the extended amygdala.
Topics: Amygdala; Analgesics; Animals; C-Reactive Protein; Cell Count; Clonidine; Dose-Response Relationship | 2003 |
Convincing effects of clonidine on neurohumoral withdrawal symptoms during antagonist-supported detoxification of opioid addicts.
Topics: Adrenergic alpha-Agonists; Clonidine; Humans; Narcotic Antagonists; Opioid-Related Disorders; Substa | 2003 |
The emperor' s new clothes.
Topics: Analgesics, Opioid; Buprenorphine; Clinical Trials as Topic; Clonidine; Heroin Dependence; Humans; M | 2003 |
Unexpected delirium during Rapid Opioid Detoxification (ROD).
Topics: Adult; Alcohol Withdrawal Delirium; Clonidine; Diagnostic and Statistical Manual of Mental Disorders | 2004 |
Management of opiate detoxification in jails.
Topics: Acute Disease; Adrenergic alpha-Agonists; Clonidine; Health Care Surveys; Humans; Methadone; Narcoti | 2005 |
[Methadone and sleep apnea syndrome].
Topics: Adult; Brain; Clonidine; Cocaine-Related Disorders; Dose-Response Relationship, Drug; Drug Administr | 2005 |
Opiate detoxification: what are the goals?
Topics: Analgesics, Opioid; Buprenorphine; Clonidine; Goals; Humans; Opioid-Related Disorders | 2005 |
Methods of detoxification and their role in treating patients with opioid dependence.
Topics: Anesthesia, General; Buprenorphine; Clonidine; Female; Heroin Dependence; Humans; Male; Naltrexone; | 2005 |
Topiramate in opiate withdrawal- comparison with clonidine and with carbamazepine/mianserin.
Topics: Adrenergic alpha-Agonists; Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Carbama | 2004 |
Induction of patients with moderately severe methadone dependence onto buprenorphine.
Topics: Adult; Buprenorphine; Clonidine; Drug Administration Schedule; Female; Humans; Male; Methadone; Narc | 2005 |
Detoxification and treating opioid dependence.
Topics: Anesthesia, General; Buprenorphine; Clonidine; Humans; Naltrexone; Narcotic Antagonists; Opioid-Rela | 2006 |
Detoxification and treating opioid dependence.
Topics: Anesthesia, General; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans; Naltrexone; Narcot | 2006 |
Combined buprenorphine and chlonidine for short-term opiate detoxification: patient perspectives.
Topics: Buprenorphine; Clonidine; Drug Combinations; Female; Humans; Inactivation, Metabolic; Male; Narcotic | 2006 |
Acute pain management for opioid dependent patients.
Topics: Adrenergic alpha-Agonists; Analgesia; Clonidine; Drug Administration Schedule; Drug Tolerance; Human | 2006 |
Client and counselor attitudes toward the use of medications for treatment of opioid dependence.
Topics: Adult; Ambulatory Care; Attitude of Health Personnel; Buprenorphine; Clonidine; Counseling; Culture; | 2007 |
Using buprenorphine short-term taper to facilitate early treatment engagement.
Topics: Adult; Analgesics; Analgesics, Opioid; Analysis of Variance; Buprenorphine; Clonidine; Drug Administ | 2007 |
Diphenoxylate hydrochloride dependency.
Topics: Adult; Antidiarrheals; Clonidine; Diphenoxylate; Dose-Response Relationship, Drug; Drug Therapy, Com | 2007 |
Naltrexone in addicted business executives and physicians.
Topics: Administrative Personnel; Adult; Aftercare; Ambulatory Care; Clonidine; Commerce; Female; Hospitaliz | 1984 |
Clonidine hydrochloride detoxification from methadone treatment--the value of naltrexone aftercare.
Topics: Adult; Aftercare; Attitude to Health; Clonidine; Female; Follow-Up Studies; Humans; Male; Methadone; | 1984 |
Clonidine for outpatient opiate detoxification.
Topics: Clonidine; Humans; Opioid-Related Disorders; Outpatients; Substance Withdrawal Syndrome | 1980 |
Rapid opiate detoxification with clonidine and naloxone.
Topics: Clonidine; Humans; Methods; Naloxone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1980 |
Treatment of opiate-withdrawal symptoms.
Topics: Adrenergic beta-Antagonists; Clonidine; Endorphins; Humans; Opioid-Related Disorders; Substance With | 1980 |
Clonidine for opiate withdrawal.
Topics: Clonidine; Humans; Opioid-Related Disorders; Receptors, Opioid; Substance Withdrawal Syndrome | 1980 |
Clonidine and opiate withdrawal.
Topics: Clonidine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1980 |
Lofexidine, a clonidine analogue effective in opiate withdrawal.
Topics: Clonidine; Humans; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1981 |
How clonidine works in easing opiate withdrawal.
Topics: Adrenergic alpha-Agonists; Clonidine; Humans; Opioid-Related Disorders; Substance Withdrawal Syndrom | 1982 |
A historical and biological overview: brain transmitters, receptors single cells, and a new treatment for opiate addiction.
Topics: Brain; Clonidine; Epinephrine; Humans; Locus Coeruleus; Neurons; Neurotransmitter Agents; Norepineph | 1982 |
Narcotic bowel syndrome treated with clonidine. Resolution of abdominal pain and intestinal pseudo-obstruction.
Topics: Abdomen; Adult; Analgesics, Opioid; Clonidine; Female; Humans; Intestinal Obstruction; Intestinal Ps | 1984 |
Clonidine for opiate withdrawal in the chronic pain patient.
Topics: Clonidine; Humans; Opioid-Related Disorders; Pain, Intractable; Receptors, Opioid; Substance Withdra | 1982 |
Neuroanatomical sites of action of clonidine in opiate withdrawal: the locus coeruleus connection.
Topics: Animals; Clonidine; Dopamine; Endorphins; Humans; Locus Coeruleus; Naloxone; Norepinephrine; Opioid- | 1981 |
The primate locus coeruleus and effects of clonidine on opiate withdrawal.
Topics: Animals; Behavior, Animal; Clonidine; Electric Stimulation; Enkephalins; Fear; Humans; Locus Coerule | 1982 |
[Effects of clonidine on opiate withdrawal symptoms. Results - biochemical mechanisms (author's transl)].
Topics: Adult; Clonidine; Female; Humans; Male; Norepinephrine; Opioid-Related Disorders; Receptors, Adrener | 1982 |
Opioid dependence and cross-dependence in the isolated guinea-pig ileum.
Topics: Animals; Clonidine; Drug Tolerance; Electric Stimulation; Guinea Pigs; Humans; Ileum; In Vitro Techn | 1982 |
The role of interaction between opiate receptors and alpha-adrenergic receptors in tolerance and dependence.
Topics: Adenylyl Cyclase Inhibitors; Animals; Brain; Cell Line; Clonidine; Cyclic AMP; Drug Interactions; Dr | 1983 |
Adaptation of a neuron to normorphine and clonidine.
Topics: Acetylcholine; Animals; Cells, Cultured; Clonidine; Drug Tolerance; Electric Stimulation; Guinea Pig | 1983 |
Recent advances in opiate detoxification: clonidine and lofexidine.
Topics: Clonidine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1983 |
Self-administration of clonidine and oxazepam by methadone detoxification patients.
Topics: Adult; Clonidine; Humans; Male; Methadone; Opioid-Related Disorders; Oxazepam; Psychomotor Performan | 1984 |
Naltrexone in addicted physicians and business executives.
Topics: Clonidine; Commerce; Humans; Naltrexone; Opioid-Related Disorders; Physicians; Socioeconomic Factors | 1984 |
Naltrexone induction: psychologic and pharmacologic strategies.
Topics: Ambulatory Care; Behavior Therapy; Clonidine; Counseling; Drug Administration Schedule; Drug Therapy | 1984 |
Finds clonidine effective in treating narcotic addicts.
Topics: Clonidine; Humans; Opioid-Related Disorders | 1984 |
Opiate withdrawal with clonidine.
Topics: Clonidine; Humans; Methadone; Nursing Assessment; Opioid-Related Disorders; Substance Withdrawal Syn | 1983 |
[Pharmacology of clonidine and its clinical application].
Topics: Animals; Blood Pressure; Brain; Clonidine; Humans; Hypertension; Migraine Disorders; Opioid-Related | 1983 |
Naltrexone and clonidine: alternatives to methadone.
Topics: Clonidine; Humans; Naloxone; Naltrexone; Opioid-Related Disorders | 1983 |
Four cases of clonidine abuse.
Topics: Adult; Clonidine; Female; Humans; Male; Opioid-Related Disorders; Substance Withdrawal Syndrome; Sub | 1983 |
Influence of clonidine on the acute dependence response elicited in naive rats by naloxone.
Topics: Animals; Clonidine; Corticosterone; Dose-Response Relationship, Drug; Drug Interactions; Humans; Mal | 1983 |
The dexamethasone suppression test for major depression among opiate addicts.
Topics: Adult; Clonidine; Depressive Disorder; Dexamethasone; Heroin Dependence; Humans; Hydrocortisone; Met | 1984 |
[Clonidine in opiate withdrawal. I. Principles of application (author's transl)].
Topics: Clonidine; Humans; Methadone; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1982 |
[Clonidine in opiate withdrawal. II. Potential side-effects].
Topics: Aggression; Anxiety; Clonidine; Depression; Humans; Narcotics; Opioid-Related Disorders; Psychoses, | 1982 |
[Clonidine in opiate withdrawal. III. Pros and cons of administration].
Topics: Clonidine; Humans; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome; Substance-Rel | 1982 |
Opiate detoxification using lofexidine.
Topics: Antihypertensive Agents; Clonidine; Humans; Male; Methadone; Opioid-Related Disorders | 1982 |
Lofexidine blocks acute opiate withdrawal.
Topics: Antihypertensive Agents; Clonidine; Humans; Methadone; Opioid-Related Disorders; Substance Withdrawa | 1982 |
Clonidine in opiate withdrawal.
Topics: Clonidine; Humans; Methadone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1983 |
Clonidine suppresses the opioid abstinence syndrome without clonidine-withdrawal symptoms: a blind inpatient study.
Topics: Adult; Clonidine; Double-Blind Method; Female; Humans; Male; Methadone; Opioid-Related Disorders; Su | 1980 |
Serum prolactin and opiate withdrawal.
Topics: Clonidine; Dopamine; Humans; Male; Opioid-Related Disorders; Prolactin; Substance Withdrawal Syndrom | 1980 |
Clonidine: inpatient studies from 1978 to 1981.
Topics: Animals; Clonidine; Dose-Response Relationship, Drug; Endorphins; Humans; Locus Coeruleus; Neural In | 1982 |
Outpatient opiate detoxification with clonidine.
Topics: Ambulatory Care; Clonidine; Double-Blind Method; Drug Therapy, Combination; Heroin Dependence; Human | 1982 |
Clonidine: basic and clinical perspectives.
Topics: Animals; Clonidine; Humans; Locus Coeruleus; Methoxyhydroxyphenylglycol; Norepinephrine; Opioid-Rela | 1982 |
The use of clonidine for management of opiate abstinence in a chronic pain patient.
Topics: Adult; Chronic Disease; Clonidine; Humans; Levorphanol; Male; Opioid-Related Disorders; Pain; Substa | 1982 |
Clinical note: use of clonidine to detoxify opiate-addicted patients.
Topics: Adult; Clonidine; Female; Humans; Male; Opioid-Related Disorders | 1982 |
[Clonidine in withdrawal therapy of opiate abuse].
Topics: Adult; Clonidine; Female; Humans; Male; Opioid-Related Disorders | 1981 |
Clonidine for narcotic withdrawal.
Topics: Clonidine; Humans; Methadone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1981 |
Clonidine in neonatal narcotic-abstinence syndrome.
Topics: Clonidine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Opioid-Related Disorders; Substance W | 1981 |
Clonidine decreases opiate withdrawal-related anxiety: possible opiate noradrenergic interaction in anxiety and panic.
Topics: Adult; Anxiety; Clonidine; Double-Blind Method; Fear; Humans; Male; Norepinephrine; Opioid-Related D | 1980 |
Clonidine and naloxone for rapid opiate detoxication: comparison between treatments.
Topics: Clonidine; Female; Humans; Male; Naloxone; Narcotics; Opioid-Related Disorders | 1981 |
Clonidine in opiate withdrawal.
Topics: Clonidine; Humans; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1981 |
The clinical use of clonidine in outpatient detoxification from opiates.
Topics: Clonidine; Dose-Response Relationship, Drug; Heroin Dependence; Humans; Methadone; Naltrexone; Opioi | 1981 |
Opiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment.
Topics: Brain; Chronic Disease; Clonidine; Diastole; Drug Evaluation; Humans; Male; Opioid-Related Disorders | 1980 |
Effect of methadone dosage on clonidine detoxification efficacy.
Topics: Clonidine; Double-Blind Method; Humans; Male; Methadone; Opioid-Related Disorders; Substance Withdra | 1980 |
Clonidine in acute opiate withdrawal.
Topics: Clonidine; Humans; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1980 |
Iatrogenic opiate addiction: successful detoxification with clonidine.
Topics: Clonidine; Codeine; Female; Humans; Middle Aged; Opioid-Related Disorders; Oxycodone; Pain, Intracta | 1980 |
Clonidine for opiate detoxification: outpatient clinical trials.
Topics: Ambulatory Care; Clonidine; Dose-Response Relationship, Drug; Heroin Dependence; Humans; Methadone; | 1980 |
Lofexidine based regimen for opiate addicts.
Topics: Clonidine; Humans; Opioid-Related Disorders; Pilot Projects; Substance Withdrawal Syndrome | 1995 |
A study of the use of clonidine and naltrexone in the treatment of opioid addiction in the former USSR.
Topics: Adult; Clonidine; Cross-Cultural Comparison; Dose-Response Relationship, Drug; Drug Administration S | 1994 |
Role of noradrenergic hyperactivity in neonatal opiate abstinence.
Topics: Adrenergic alpha-Agonists; Animals; Animals, Newborn; Brain; Clonidine; Humans; Infant, Newborn; Met | 1996 |
Propofol for sedation during rapid opiate detoxification.
Topics: Adult; Clonidine; Humans; Hypnotics and Sedatives; Infusions, Intravenous; Male; Naloxone; Opioid-Re | 1997 |
What you need to know: addiction--cough mixture.
Topics: Acute Disease; Adrenergic alpha-Agonists; Antitussive Agents; Chronic Disease; Clonidine; Codeine; D | 1997 |
Illicit use of clonidine in opiate-abusing pregnant women.
Topics: Adult; Antihypertensive Agents; Case-Control Studies; Clonidine; Female; Humans; Opioid-Related Diso | 1997 |
[Detoxication in opiate addiction and prevention of recurrence: administration of naltrexone and cognitive behavior therapy].
Topics: Adrenergic alpha-Agonists; Adult; Behavior Therapy; Clonidine; Combined Modality Therapy; Female; Hu | 1997 |
A naturalistic study of home detoxification from opiates using lofexidine.
Topics: Adult; Clonidine; Female; Heroin Dependence; Humans; Inactivation, Metabolic; Male; Methadone; Narco | 1998 |
Effects of tizanidine administration on precipitated opioid withdrawal signs in rats.
Topics: Adrenergic alpha-Agonists; Analgesics; Analysis of Variance; Animals; Behavioral Symptoms; Body Temp | 1998 |
Outcomes of ultrarapid opiate detoxification combined with naltrexone maintenance and counseling.
Topics: Adult; Anesthesia, General; Clonidine; Combined Modality Therapy; Counseling; Follow-Up Studies; Hum | 1998 |
Rapid opioid detoxification.
Topics: Adrenergic alpha-Agonists; Anesthesia; Clonidine; Humans; Naloxone; Narcotic Antagonists; Opioid-Rel | 1998 |
Opioid detoxification in pregnancy.
Topics: Adult; Analgesics; Analgesics, Opioid; Chi-Square Distribution; Clonidine; Drug Therapy, Combination | 1998 |
Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway.
Topics: 4-Aminopyridine; Adenylyl Cyclases; Adrenergic alpha-Agonists; Animals; Clonidine; Cyclic AMP-Depend | 1998 |
Catecholamine surge in opioid-addicted patients undergoing detoxification under general anesthesia.
Topics: Adrenergic alpha-Agonists; Anesthesia, General; Catecholamines; Clonidine; Humans; Naloxone; Narcoti | 1999 |
The use of lofexidine by drug dependency units in the United Kingdom.
Topics: Adolescent; Adult; Clonidine; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; N | 1999 |
Attention deficit hyperactivity disorder and treatment outcome in opioid abusers entering treatment.
Topics: Adult; Ambulatory Care; Attention; Attention Deficit Disorder with Hyperactivity; Clonidine; Cogniti | 1999 |
Opioid detoxification under anaesthesia.
Topics: Adrenergic alpha-Agonists; Anesthesia, General; Clonidine; Cyclic AMP; Cyclic AMP Response Element-B | 2000 |
Two methods of community detoxification from opiates: an open-label comparison of lofexidine and buprenorphine.
Topics: Adult; Buprenorphine; Chi-Square Distribution; Clonidine; Community Health Services; Female; Humans; | 2001 |
Outcomes of naltrexone maintenance following ultra rapid opiate detoxification versus intensive inpatient detoxification.
Topics: Adult; Analgesics; Clonidine; Humans; Inactivation, Metabolic; Israel; Male; Naltrexone; Narcotic An | 2002 |
Dorsal and median raphe serotonergic system lesion does not alter the opiate withdrawal syndrome.
Topics: 5,7-Dihydroxytryptamine; Adrenergic alpha-Agonists; Animals; Behavior, Animal; Biogenic Amines; Clon | 2002 |
Clonidine detoxification: a fourteen-day protocol for rapid opiate withdrawal.
Topics: Clonidine; Humans; Methadone; Opioid-Related Disorders; Substance Withdrawal Syndrome; Time Factors | 1979 |
Clonidine hydrochloride: a nonopiate treatment for opiate withdrawal.
Topics: Clonidine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1979 |
A rationale for opiate withdrawal symptomatology.
Topics: Animals; Clonidine; Endorphins; Humans; Locus Coeruleus; Norepinephrine; Opioid-Related Disorders; R | 1979 |
The relationship between craving, anxiety, and other symptoms in opioid withdrawal.
Topics: Anxiety; Clonidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Motivati | 1992 |
Mr R: a case study of withdrawal.
Topics: Alcoholism; Clonidine; Cocaine; Humans; Male; Methadone; Middle Aged; Neurologic Examination; Opioid | 1992 |
Methadone maintenance and clonidine detoxification in the treatment of opiate addicts in Israel: suggesting evidence for cultural differences in the effectiveness of treatment modalities for opiate addiction.
Topics: Antidepressive Agents; Clonidine; Combined Modality Therapy; Cross-Cultural Comparison; Culture; Emp | 1991 |
Self-administration of clonidine, oxazepam, and hydromorphone by patients undergoing methadone detoxification.
Topics: Adult; Clonidine; Drug Administration Schedule; Humans; Hydromorphone; Male; Methadone; Opioid-Relat | 1985 |
A novel action of morphine in the rat locus coeruleus: persistent decrease in adenylate cyclase.
Topics: Adenylyl Cyclases; Animals; Clonidine; Dose-Response Relationship, Drug; Drug Tolerance; Enkephalin, | 1989 |
Naltrexone treatment--the problem of patient acceptance.
Topics: Adult; Clonidine; Female; Follow-Up Studies; Humans; Male; Methadone; Naltrexone; Opioid-Related Dis | 1989 |
The role of drugs in the treatment of opioid addicts.
Topics: Alcoholism; Anxiety; Clonidine; Dextropropoxyphene; Heroin; Humans; Inactivation, Metabolic; Kinetic | 1986 |
Effects of pentazocine and concomitant clonidine on opioid receptors in the rat brain.
Topics: Animals; Brain; Clonidine; Humans; Male; Naloxone; Opioid-Related Disorders; Pentazocine; Rats; Rats | 1985 |
Propranolol and clonidine in detoxification.
Topics: Clonidine; Humans; Lorazepam; Methadone; Opioid-Related Disorders; Propranolol; Psychomotor Agitatio | 1988 |
Propranolol as adjunct to clonidine in opiate detoxification.
Topics: Adult; Clonidine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Opioid-Related Disor | 1987 |
Opiate and cocaine dependencies. Techniques to help counter the rising tide.
Topics: Ambulatory Care; Blood Pressure; Clonidine; Cocaine; Drug Tolerance; Hospitalization; Humans; Opioid | 1985 |
[Less known indications for the use of clonidine].
Topics: Alcohol Amnestic Disorder; Brain Diseases; Clonidine; Glaucoma; Humans; Migraine Disorders; Opioid-R | 1985 |
Use of guanabenz in methadone withdrawal.
Topics: Adult; Clonidine; Female; Guanabenz; Guanidines; Humans; Methadone; Opioid-Related Disorders; Substa | 1985 |